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ABSTRACT
Ebola virus (EBOV) is an extremely contagious pathogen and causes lethal hemorrhagic fever
disease in man and animals. The recently occurred Ebola virus disease (EVD) outbreaks in the
West African countries have categorized it as an international health concern. For the virus
maintenance and transmission, the non-human primates and reservoir hosts like fruit bats have
played a vital role. For curbing the disease timely, we need effective therapeutics/prophylactics,
however, in the absence of any approved vaccine, timely diagnosis and monitoring of EBOV
remains of utmost importance. The technologically advanced vaccines like a viral-vectored
vaccine, DNA vaccine and virus-like particles are underway for testing against EBOV. In the
absence of any effective control measure, the adaptation of high standards of biosecurity
measures, strict sanitary and hygienic practices, strengthening of surveillance and monitoring
systems, imposing appropriate quarantine checks and vigilance on trade, transport, and
movement of visitors from EVD endemic countries remains the answer of choice for tackling
the EBOV spread. Herein, we converse with the current scenario of EBOV giving due emphasis
on animal and veterinary perspectives along with advances in diagnosis and control strategies
to be adopted, lessons learned from the recent outbreaks and the global preparedness plans.
To retrieve the evolutionary information, we have analyzed a total of 56 genome sequences of









The entry of Ebola virus disease (EVD) was first marked in
the year 1976 (Vogel & Viale 2014) and since then it is a
highly contagious virus infection leading to the death of
large numbers of humans (Muyembe-Tamfum et al.
2012; Bausch & Schwarz 2014; Bellizzi 2014; Dhama,Malik,
et al. 2015). The disease is zoonotic, and evidence sug-
gests the involvement of fruit bats as the main reservoir
(Towner et al. 2007; Towner et al. 2008; Spengler et al.
2016; Hassanin et al. 2016; Judson et al. 2016). Although it
affects both human and non-human primates, the major
outbreaks have been reported in humans, mostly in
Western Africa (Weingart et al. 2013; Feldmann & Feld-
mann 2014; Shrivastava et al. 2015a, 2015b). The Ebola
virus (EBOV) has been listed as Category A agent warrant-
ing biosafety containment level 4 (BSL4) for the handling
of suspected samples. The disease symptoms start with
fever, pain in stomach with vomiting and diarrhea,
bleeding, intravascular coagulation, multisystem organ
failure, and hypovolemic shock and in terminal cases, the
patient succumbs to death (Mendoza et al. 2015). The
virus spreads from diseased to normal persons through
direct contact and infected materials. This virus tends to
persist in body leading to further complications such as
loss of vision (Shantha et al. 2017), hearing (Hebert et al.
2017), etc. along with transmission through semen from
male to female (Hartmann et al. 2017) and to fetus at the
time of pregnancy (Friedrich 2016; Wiwanitkit 2016).
A major outbreak of EBOV, which occurred in 2014
in Western African countries, transpired to several
other countries in a short span of time, culminating it
as an alarming situation world over. The spread of
EBOV was so rapid that family members and the com-
munity around infected people suffered sternly (Kuhn
et al. 2010; Weingart et al. 2013; Gatherer 2014). Of
note, affected young children showed comparatively
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shorter incubation period and rapid course of disease
with high mortality (Team 2015). Owing to global trade
and tourism, there is every possible opportunity that
EBOV can spread to other continents where it may
lead to massive outbreaks. The epidemics which
occurred over the past few years should serve as an
eye-opener to the world so that everyone is well pre-
pared for the next pandemic if any occurs. In this direc-
tion, it is important that the nature of the agent, its
evolution pattern, and pathway of spread must be
understood at a subtle level. To deal with such a highly
spreading disease we must be equipped with rapid
state-of-art diagnostics which are useful at the bedside
of the patient, ultimately benefiting in opting appropri-
ate control and treatment measures. Likewise, there is
an urgent need to have effective and adequate vac-
cines to provide protection to the population at high
risk. Therapeutic strategies must be evaluated for their
high potential.
Currently, there are five distinct EOBV species which
have been described, and four of them (Zaire ebolavi-
rus, Sudanebolavirus, Ta€ı Forest ebolavirus, and Bundibu-
gyo ebolavirus) cause disease in humans, whereas the
Reston ebolavirus is known to cause disease in non-
human primates solely. We here converse comprehen-
sively over the developments ensued in understanding
the etiopathology of EVD, ecology, prevention and
control strategies along with various therapeutic
alternatives.
2. The virus and its genome
EBOV belongs to the order Mononegavirale (single-
stranded, non-segmented, negative-sense RNA virus)
of the family Filoviridae, genus Ebolavirus. Other mem-
bers of the family include Marburgvirus and Cuevavirus,
of which Marburgvirus has also been implicated in
causing hemorrhagic diseases similar to EBOV, and
both of these are filamentous shape viruses. The genus
Marburgvirus consists of a species Marburg marburgvi-
rus with two viruses viz., Marburg virus (MARV) and
Ravn virus (RAVV). The genus Cuevavirus consists of a
single species – Lloviu cuevavirus with Lloviu virus
(LLOV). The EBOV was first isolated in 1976 near Zaire
valley in the Democratic Republic of Congo (Zaire)
rooting its name from the place of isolation (Kuhn et al.
2010), initially named as an Ebola-like virus which was
later changed into EBOV in the year 2002. The genus
Ebolavirus consists of five species viz., (1) Zaire ebolavi-
rus (Zaire virus – ZEBOV), (2) Sudan ebolavirus (Sudan
virus – SUDV), (3) Reston ebolavirus (Reston virus –
RESTV), (4) Ta€ı Forest ebolavirus (Ta€ı Forest virus –
TAFV), and (5) Bundibugyo ebolavirus (Bundibugyo
virus – BDBV) and Côte d'Ivoire ebolavirus (CIEBOV)
(Kuhn et al. 2013; Bausch & Schwarz 2014; Bukreyev
et al. 2014; Kuhn, Andersen, et al. 2014; Kuhn, Bao,
et al. 2014; http://www.ictvonline.org/virusTaxonomy.
asp). The genetic diversity among species in the genus
Ebolavirus ranges between 25% and 35% (Grard et al.
2011). Among the five species, ZEBOV and SUDV are
extremely deadly, of which the former is most danger-
ous with more than 90% lethality (Bellizzi 2014; Toit
2014; Safari et al. 2015). ZEBOV was frequently docu-
mented in Central Africa and has caused the major out-
breaks recently in Western African countries like
Nigeria, Liberia, Guinea, Senegal, and Sierra Leone
(Baize et al. 2014).
As shown in Figure 1, structurally the virions of filovi-
rus show pleomorphism which includes long filaments
(Latin-filum means thread), shaped like a ‘6’, a ‘U’, or a
circle. Viral filaments are 80 nm in diameter with up to
14,000 nm in length and are enveloped in a lipid mem-
brane (http://www.cdc.gov/vhf/virus-families/filoviridae.
html). The genome of EBOV is 19 kb in length, consists
of seven genes which are arranged as – 3" (leader)- NP-
VP35-VP40-GP-VP30-VP24-L-(trailer) 5" (Volchkov et al.
1999). These seven open reading frames encode struc-
tural nucleoprotein (NP), envelope glycoprotein (GP),
and matrix proteins like viral proteins (VP24) (mem-
brane-associated protein) and VP40. Except for GP, each
of these genes encodes a single protein product. Apart
from structural proteins, L (RNA polymerase), VP30 and
VP35 (both polymerase matrix proteins) correspond to
the major non-structural protein. These proteins exhibit
different roles in virus pathogenesis like VP24 inhibits
interferon signaling, VP35 is an antagonist of interferon,
whereas VP40 has a role in budding and release of the
virus (Feldmann & Geisbert 2011). VP40 has been
recently found in the extracellular region like exosome
that can affect the immune system of the host (Pleet
et al. 2017). The GP gene codes for three different ver-
sions of GP, namely GP (contains GP1 attachment pro-
tein and the GP2 fusion/entry protein), soluble form
(sGP – is produced from the unedited RNA transcript)
and small soluble form (ssGP – is a truncated version of
sGP). Most of these proteins have multiple functions. NP
facilitates the genomic RNA encapsidation to form RNP
complex (RNA + NP + + L), which plays an essential role
in virus replication. The GP and VP40 are essential com-
ponents of the viral envelope. GP has a role in virus
attachment, entry, causing cell rounding, down-regulat-
ing host surface proteins, causes inflammation, cell
damage, and cytotoxicity (Casillas et al. 2003; Geisbert
et al. 2009; Olival et al. 2013). The nucleocapsid consists
of the viral RNA complexed with five proteins, namely
NP, VP24, VP30 and VP35, and L (Sanchez et al. 1993;
Lee & Saphire 2009; Bharat et al. 2012; Basler 2014;
Brauburger et al. 2014; Gallaher & Garry 2015; Dong
et al. 2015; Jun et al. 2015). Unlike influenza A virus, the
rate of genetic change is very slow in EBOV, but this
virus diverged several thousand years ago (Suzuki &
Gojobori 1997; Taylor et al. 2011).
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2.1. Evolutionary picture of Ebolaviruses
To retrieve the evolutionary information, we have ana-
lyzed a total of 56 genome sequences of various EBOV
species submitted between 1976 and 2016 in public
database, wherein the Zaire, Sudan, Reston, Ta€ı, and
Bundi EBOVs formed distinct clades (Figure 2). The
ZEBOV strains organized into two distinct sub-clades,
sub-clade 1 comprising of the isolates from Gabon and
the Democratic Republic of Congo and sub-clade 2
clubed Sierra Leone and Liberia isolates (Figure 2). The
evolutionary divergence between the species was esti-
mated using the Maximum Composite Likelihood
model (Tamura et al. 2004). The number of transver-
sional substitutions per site from the average of overall
sequence pairs between groups was obtained. The
rate variation among sites was modeled with a gamma
distribution (shape parameter = 1). Codon positions
included were 1st + 2nd + 3rd + Noncoding. There was
a total of 17,999 positions in the final data-set. Evolu-
tionary analyses were conducted in MEGA6 (Tamura
et al. 2013). Further, the analysis revealed that the Ta€ı
and Bundi EBOVs remain closely related to 17.8%
mean group diversity; the ZEBOV had the mean group
diversity of 26.1% and 26.8%, respectively with Ta€ı and
Bundi EBOV. The SUDV outgroup from ZEBOV, Ta€ı, and
Bundi EBOVs revealed mean group diversity of 36.3%,
37.4%, and 37.6%, respectively. Similarly, RESTV out-
group from Zaire, Ta€ı, and Bundi EBOVs came up with
mean group diversity of 34.1%, 35.1%, and 34.8%,
respectively. Likewise, the mean group diversity
between Sudan and Reston EBOVs was found to be
36.6%.
2.2. Epidemiology, transmission, and spread
It is evident that since the first report of EVD, the num-
ber of ratified cases has increased several folds. The
causality cases of EVD almost doubled in Africa in com-
parison to the earlier reported cases of the last four
decades (6458 deaths out of 12,299 cases; Muyembe-
Tamfum et al. 2012; Tambo et al. 2014; Bellizzi 2014)
and the cases reported between 2014 and 2016
(12,922 deaths out of 31,079 cases) (CDC 2015)
(Table 1). The 2014–2015 outbreak was assumed to be
the biggest epidemic in the history of this disease
(Gatherer 2014; Zhang & Wang 2014; Elstona et al.
2017). Though several strains of EBOV have been iden-
tified in the past, the 2014–2015 outbreak affecting
Figure 1. Structure of Ebola virus and its genome. Ebola virus possesses negative-sense RNA genome with exceptionally 14000 nm
length with 3' nucleoprotein and 5' RNA polymerase end.
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Figure 2. Evolutionary relationships of Ebola virus complete genomes. The evolutionary history was inferred using the Neighbor-
Joining method (Saitou & Nei 1987). The optimal tree with the sum of branch length = 1.06917633 is shown. The percentage of rep-
licate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) is shown next to the branches
(Felsenstein 1985). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to
infer the phylogenetic tree. The evolutionary distances were computed using the p-distance method (Nei & Kumar 2000) and are in
the units of the number of base differences per site. The analysis involved 56 nucleotide sequences. Codon positions included were
1st + 2nd + 3rd + Noncoding. All positions containing gaps and missing data were eliminated. There was a total of 17,999 positions
in the final data-set. Evolutionary analyses were conducted in MEGA6 (Tamura et al. 2013).
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mainly Western African countries (Guinea, Sierra Leone,
Liberia, Senegal, and Nigeria) was confirmed due to
ZEBOV (Bellizzi 2014). This strain was the first EBOV
which caused the historic 1976 Ebola case affecting a
middle age school teacher in the Democratic Republic
of the Congo (Johnson 1978). Identifying the severity
and out-of-control situation about EVD, the World
Health Organization declared it as a ‘Public Health
Emergency of International Concern’ (PHEIC). Owing to
its high virulence and fast transmission capability, it is
categorized under ‘class A’ bio-weapon organism (Bal-
mith et al. 2016) and thus making it essential to have
real-time monitoring of EVD cases and to look into any
connectivity among the cases. For this, use of smart
mobile phones reporting of EVD cases in West Africa
was encouraged by epidemiologists as an effective
technique. Use of social network analysis in this way
will certainly help in understanding disease spread in a
better way (Kangbai 2016). The case fatality rate
observed in Ebola-affected cases in different countries
varied between 25% and 100%.
The countries affected during 1976–2016 are
depicted in Figure 3 and a historical timeline of EBOV
is presented in Figure 4. The disease outbreaks caused
by different EBOV species are given in Table 1 and
chronological data of EBOV cases and fatality since its
first incidence is summarized in Table 2.
2.2.1. Zaire ebolavirus (ZEBOV)
The first known Ebola outbreak occurred in 1976 in
Sudan (later the causative agent was classified under
Sudan virus – SUDV) and the Democratic Republic of
the Congo (DRC; previously known as Zaire) (Report of
an International Commission 1978; Report of a WHO/
International Study Team 1978) (Figures 3 and 4). In
the DRC outbreak (between September and October
1976), 318 cases of acute viral hemorrhagic fever (VHF)
with 280 deaths (case fatality rate – CFR 88%) occurred
in and around the Yambuku region. The duration of
the clinical disease was about one week with non-spe-
cific symptoms for the initial four days followed by a
severe sore throat, maculopapular rash, abdominal
pain, and bleeding from multiple sites – mainly from
the gastrointestinal tract. The causative agent could be
isolated from eight cases using Vero cell cultures and
was named as Ebola virus (Report of an International
Commission 1978). The index case (the first identified
case) was a 44-year-old male instructor who has been
treated for presumptive malaria at the Yambuku
hospital, and from there the subsequent outbreaks
emerged.
The first EBOV was isolated in 1976 (isolate E718)
from the blood sample of a 42-year-old Belgian nursing
sister (patient No. 718) who was working at Mission
Hospital, Yambuku, DRC. The sister (Myriam Louise
Ecran) was one of the first victims of Ebola hemor-
rhagic fever (EHF) and died on 30 September 1976
(CDC 2015; www.bbc.com/news/magazine-28262541).
Researchers decided to name the virus to the nearby
river – the Ebola, rather than the village name to avoid
stigma to that village. In Belgian, the river named as
l'Ebola (the indigenous Ngbandi name is Legbala)
means ‘white water’ or ‘pure water’ (Report of an Inter-
national Commission 1978; Report of a WHO/



















28,652 11,325 (40) Data between March 2014 and 27 March 2016.
Seven countries (Italy, Mali, Nigeria, Senegal,
Spain, the United Kingdom, and the United
States of America) have previously reported a
case or cases imported from a country with
widespread and intense transmission.
Ebolavirus 1 DRC 66 49 (74) August–November 2014; the outbreak was





Bundibugyo virus 2 DRC, Uganda 185 50 (27)
Reston virus 7 Philippines, USA, Italy 13 0 (0) Four outbreaks in monkeys only; one outbreak
in pigs with antibody detection in six workers;
two out breaks in moneys with seven people
developed antibodies.
Sudan virus 8 South Sudan, Uganda,
England
779 412 (53)
Ta€ı Forest virus 1 Côte d'Ivoire (Ivory
Coast)
1 0 (0)
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International Study Team 1978). Since that time, the
name Ebola has been used (http://www.nature.com/
scitable/blog/viruses101/the_scientist_who_discovere
d_ebola). The EBOV was initially categorized as ‘Mar-
burg-like’ due to the morphological resemblance
(Johnson et al. 1977). Initially, it was presumed that the
DRC and Sudan outbreaks were caused by the same
strain of the virus (the distance between Yambuku and
Nzara is about 800 km) but, later it was realized that
there is involvement of two distinct species, namely
Zaire Ebola virus (Ebola virus – ZEBOV) and Sudan ebo-
lavirus (Sudan virus – SUDV), respectively (McCormick
et al. 1983; Pourrut et al. 2005; Muyembe-Tamfum et al.
2012).
Figure 3. Ebola-affected countries on the world map. The coloured area depicts Ebola presence from 1976 to 2016.
Figure 4. Historical timeline of Ebola virus. The number of outbreaks in Sudan, the Democratic Republic of Congo, Uganda, and Tai
Forest are dipcted.
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The subsequent outbreak of EBOV occurred in June
1977 in Tanda (325 km from Yambuku), DRC and a
nine-year-old girl died with typical clinical signs of EHF.
No secondary cases were identified (Heymann et al.
1980). Later, a less extensive form of EBOV occurred,
between July and October 1979, in Nzara and Yambio
(25 km away from Nzara), wherein 22 deaths occurred
out of 34 cases with CFR of 65% (Baron et al. 1983).
After 15 years of pause, three EBOV outbreaks
occurred in northeastern Gabon between 1994 and
1997. The first epidemic (fall 1994) occurred in
Mekouka along with co-infection of yellow fever virus.
In this epidemic, 49 cases of EVD, with 29 deaths (CFR
59%) occurred. A second epidemic (spring 1996) in
Mayibout caused 31 cases with 21 deaths (CFR 68%)
and of note a chimpanzee was suspected as the index
case. The third epidemic (fall 1996) occurred in Booue
and caused 60 cases with 45 deaths (CFR 75%). Several
chimpanzees died in this area, and EBOV-antigen could
be detected from one of the skin samples by immuno-
staining (Georges et al. 1999). Partial GP gene
sequence analysis revealed that the causative agent
behind all these three outbreaks was EBOV (Georges-
Courbot et al. 1997). Additionally, this outbreak also
led to the death of a nurse in South Africa which was
transmitted from an EBOV-infected Gabonese physi-
cian working in Libreville and traveled to Johannes-
burg for treatment (WHO 1996; Pourrut et al. 2005).
Afterwards, one of the largest EBOV outbreaks
occurred in the city of Kikwit, DRC (»500 km southeast
of Kinshasa), between January and July 1995 with 255
deaths out of 315 cases (CFR 81%). Of note, a 42-year-
old male charcoal worker was identified as index case
who had acquired infection from some natural reser-
voir such as bats, as no great apes were found in that
region (Guimard et al. 1999; Khan et al. 1999).
In Ta€ı Forest, Côte d'Ivoire, between 1996 and 1997,
autopsy samples from several species of vertebrates
including bats, rodents, insectivores, monkeys, and
birds were screened, and anti-EBOV IgG could be
detected only from a Colobe bai monkey (red colobus,
Colobus badius) (Pourrut et al. 2005). During ecological
studies in the Central African Republic (CAR) in 1998,
242 vertebrates include bats, rodents and insectivores
were captured and organs tested for the presence of
EBOV nucleic acid by GP and L genes-based reverse
Table 2. Chronological data of Ebola virus cases and fatality since its first incidence.
Years Country Cases reported Deaths Case fatality rate
1976 Zaire 318 280 88%
Sudan 284 151 53.1%
England 1 0 0%
1977 Zaire 1 1 100%
1979 Sudan 34 22 64.7%
1989–1990 Philippines 3 0 0%
1990 USA 4 0 0%
1994 Gabon 52 31 59.6%
Côte d'Ivoire Ivory Coast 1 0 0%
1995 Democratic Republic of Congo 315 250 71.4%
1996 Gabon 37 21 56.7%
1996–1997 Gabon 60 45 75%
1996 South Africa 2 1 50%
2000–2001 Uganda 425 224 52.7%
2001–2002 Gabon 65 53 81.5%
Republic of Congo 57 43 75.4%
2002–2003 Republic of Congo 143 128 89.5%
2003 Republic of Congo 35 29 82.8%
2004 South Sudan 17 7 41.1%
Russia 1 1 100%
2007 Democratic Republic of Congo 264 187 70.8%
2007–2008 Uganda 149 37 24.8%
2008 Philippines 6 0 0%
2008–2009 Democratic Republic of Congo 32 15 46.8%
2011 Uganda 1 1 100%
2012 Uganda 11 4 36.3%
Democratic Republic of Congo 36 13 36.1%
2012–2013 Uganda 6 3 50%
2014–2016 United States of America 4 1 25%
Spain 1 0 0%
United Kingdom 1 0 0%
Italy 1 0 0%
Guinea 3814 2544 66.7%
Sierra Leone 14124 3956 28%
Senegal 1 0 0%
Mali 9 6 66.6%
Liberia 10678 4810 45%
Nigeria 20 8 40%
Total 31013 12872 41.5%
Note: Data compiled from WHO situation reports apps.who.int/ebola/ebola-situation-reports?m = 20141121 and CDC updates on Ebola virus https://
www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/previous-updates.html
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transcription-polymerase chain reaction (RT-PCR).
Seven animals including six mice (Mus setulosus and
Praomys spp.) and a shrew (Sylvisorex ollula) were
found harboring EBOV (Morvan et al. 1999).
Between October 2001 and December 2003, at least
five EBOV outbreaks occurred in the border areas of
northeast Gabon and northwest Republic of Congo
(RC) with 313 cases and 265 deaths (CFR 85%). The first
outbreak (October 2001–May 2002) occurred in both
Gabon and RC; the outbreak occurred as multiple inde-
pendent epidemic chains with 92 cases and 70 deaths
(CFR 77%). Epidemiologic investigations suggest the
possible involvement of carcasses of wild animals
(bushmeat) including duikers, chimpanzees, and
gorillas in the index patients. In January 2002, in
Franceville, a single case was reported in the south of
Gabon (Nkoghe, Nnegue, et al. 2005) and the remain-
ing four outbreaks occurred only in RC.
In a later outbreak (Entsiami – January 2002 to June
2002), a total of 30 cases with 25 deaths (CFR 83%)
occurred; a gorilla and a duiker were suspected to be
the source for the index cases. In the following out-
break (Oloba – May to June 2002), 13 cases with 12
deaths (CFR 92%) occurred, and a chimpanzee was
identified as the source for index case. In another out-
break (Mbomo and Kelle – December 2002 to April
2003) 143 cases with 129 deaths (CFR 90%) occurred;
gorillas and duikers were suspected to be the source of
infection for the index cases. The last outbreak
(Mbanza and Mbomo – November 2003 and December
2003) caused 35 cases with 29 deaths (CFR 83%).
However, the source of infection could not be
traced (http://www.who.int/wer/2003/en/wer7826.pdf;
Formenty et al. 2003; Leroy et al. 2004; Pourrut et al.
2005; Rouquet et al. 2005; Nkoghe, Formenty, et al.
2005). Sequencing analysis of GP gene of EBOV
revealed that the above five human outbreaks origi-
nated from distinct animal sources and viral strains
(Leroy et al. 2004). These Gabon-RC cross-border out-
breaks were marked by large wildlife epizootics associ-
ated with over 80% mortality especially in great apes
(Leroy et al. 2004; Rouquet et al. 2005; Bermejo et al.
2006; Lahm et al. 2007; Grard et al. 2011).
After the first outbreak in the forest zone of Gabon-
RC, an Animal Mortality Monitoring Network was cre-
ated. The analysis of the samples recovered between
August 2001 and June 2003 revealed that 10 gorillas, 3
chimpanzees, and 1 duiker were positive for EBOV
infection (Rouquet et al. 2005). Another group of
researchers from Centre International de Recherches
Medicales de Franceville, Gabon analyzed a total of 34
carcasses in the same period, and 14 (10 gorillas, 3
chimpanzees, and 1 duiker) were found positive for
EBOV infection (Pourrut et al. 2005).
In the seroprevalence study of EBOV in 20 species of
non-human primates between 1985 and 2000 in
Cameroon, Gabon, and the RC, the wild chimpanzees
showed 12.9% positivity. Also, few other monkey spe-
cies (five drills, one baboon, one mandrill, and one Cer-
copithecus sp.) were also positive indicating the
complexity of the EBOV circulation and the possibility
of involvement of more reservoir species (Leroy et al.
2004; Pourrut et al. 2005).
To identify the viral reservoir in the multiple out-
breaks of Ebola in Gabon and RC between 2001 and
2005, the investigation was carried out from samples
of over 1000 small vertebrates. Anti-EBOV IgG, as well
as EBOV-specific RNA sequences, were detected from
three different bat species (Hypsignathus monstrosus,
Epomops franqueti, and Myonycteris torquata). The
sequence confirmation of EBOV indicates that bats
might serve as a natural reservoir of EBOV (Leroy et al.
2005; Pourrut et al. 2009). In a large-scale serological
survey from these three bat species which were cap-
tured between 2003 and 2006 in Gabon and RC 5%
EBOV infection positivity was shown, supporting their
potential reservoir status (Pourrut et al. 2007; Pourrut
et al. 2009). In a further extension of this study, samples
were analyzed for EBOV from nine species of bats
which were sampled between 2003 and 2008 and
among these, 4% of the total population sampled
belonged to six species (Epomops franqueti, Hypsigna-
thus monstrosus, Myonycteris torquata, Micropteropus
pusillus, Mops condylurus, and Rousettus aegyptiacus)
which revealed anti-EBOV antibodies (Pourrut et al.
2009).
The EBOV reemerged in the Luebo region of DRC in
2007 and 2008, causing two successive outbreaks. The
2007 outbreak caused 264 cases with 187 deaths (CFR
71%) and re-occurred one year later with 32 cases with
15 deaths (CFR 47%). The suspected source of the
Luebo 2007 outbreak was fruit bats (Hypsignatus mon-
strosus and Epomops franqueti). The index source of
the 2008 outbreak could not be traced out. The analy-
sis of whole-genome sequence results of viruses from
these two outbreaks confirms them almost identical
(Grard et al. 2011).
Following this, the EBOV outbreak occurred in multi-
ple villages in the DRC between July and November
2014 in Equateur province with a total of 69 cases with
49 deaths (CFR 71%). A pregnant woman was the index
case, and monkey meat was the suspected source of
the infection. A complete genome sequence from this
outbreak shared 99.2% and 96.8% identities with
EBOVs of 1995 outbreak in the DRC and current out-
break in West Africa, respectively (Maganga et al.
2014).
The recent EBOV-epidemic burst in West Africa
started in Guinea in late 2013 and spread to several
countries within a few months period (Cenciarelli et al.
2015). As of 13 April 2016, a total of 31,013 cases with
12,872 deaths (CFR 41.5%) have been reported. The
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widespread transmission occurred in three countries,
namely Liberia, Sierra Leone and Guinea (28,616 cases
with 11,310 deaths – CFR 40%). Very few travel-related
cases (36 cases and 15 deaths) have been reported in
seven countries, namely Italy, Mali, Nigeria, Senegal,
Spain, the United Kingdom, and the United States of
America) (http://www.cdc.gov/vhf/ebola/outbreaks/
2014-west-africa/case-counts.html). The suspected index
case for these outbreaks was a two-year-old child
(http://www.who.int/csr/disease/ebola/ebola-6-months/
guinea/en/). The whole-genome sequencing of 99 sam-
ples from 78 affected individuals in Sierra Leone sug-
gested the involvement of the West African variant of
EBOV in the current epidemic. The suspected source of
the outbreak was from an unknown animal reservoir.
The Sierra Leone outbreak originated from the introduc-
tion of two EBOV variants lineages (Gire et al. 2014).
Considering the highest risk to the national security
and public health concern, the US-NIAID, classified the
EBOV under Category A Priority Pathogens (https://
www.niaid.nih.gov/topics/biodefenserelated/biode
fense/pages/cata.aspx). Laboratory-acquired EBOV
infection also had been reported from Russia on two
occasions. It had emerged that in 1996, a female lab
technician carrying out the high-risk work, cut herself
when she drew blood from a horse that had been
infected with EVD and died quickly. In the second inci-
dent, a Russian lab worker died in 2004 while working






2.2.2. Sudan ebolavirus (Sudan virus – SUDV)
Sudan virus – SUDV (Sudan ebolavirus) and Ebola virus
– EBOV (Zaire ebolavirus) are related regarding clinical
disease but vary in serology, pathogenic potential, and
virological properties (Richman et al. 1983). In Sudan,
between June and November 1976, a large outbreak of
EHF occurred in Nzara, Maridi, and the surrounding
area and caused 284 cases with 151 deaths (CFR 53%).
The clinical disease observed in this outbreak was asso-
ciated with high mortality (CFR 53%) and a prolonged
recovery period in survivors. A cotton factory worker in
Nzara was identified as the index case (Report of a
WHO/International Study Team 1978). The specimens
collected during the Sudan and DRC outbreaks were
sent to high-security laboratories in England (Microbio-
logical Research Establishment, Porton Down), Belgium
(Institute of Tropical Medicine, Antwerp), and the
United States of America (CDC, Atlanta) for isolation
and identification of the agent. All three laboratories
isolated a virus that morphologically resembled Mar-
burg virus but was serologically distinct (Bowen et al.
1977; Emond et al. 1977; Johnson et al. 1977). In the
UK, one of the investigators accidentally pricked his
thumb while handling the samples and developed an
illness (Emond et al. 1977).
Between July and October 1979, SUVD outbreak
occurred in Nzara and Yambio of southern Sudan and
caused 34 cases with 22 deaths (CFR 65%). A 45-year-
old man who had been employed in the Nzara textile
factory was the index case (Baron et al. 1983), and the
possible source of infection was bats (Pourrut et al.
2005).
An outbreak of VHF occurred between October
2000 and January 2012 from Gulu district (borders
Sudan), Uganda, and 425 infected cases were reported
with 224 deaths (CFR 53%). A concurrent outbreak of
SUDV and measles occurred in Yambio County of
southern Sudan between April and June 2004. A total
of 17 VHF cases and 7 deaths (CFR 41%) were reported
in Yambio payam. The CDC confirmed the presence of
SUDV in this outbreak (WHO 2005). The index case
was a radio technician, and the source of the
outbreak was a baboon (Papio anubis) (WHO 2005).
During 2008, SUDV outbreak recurred in Kaluamba
with 37 cases and 16 deaths (CFR 44%). An 18-year-old
girl appeared to be an index case, but the source was
not known (Muyembe-Tamfum et al. 2012; Rewar &
Mirdha 2014).
In May 2011, a 12-year-old girl from Luwero,
Uganda, was admitted to the Hospital with symptoms
of VHF and died within three hours of admission. Evi-
dence of infection with SUDV was confirmed by RT-
PCR, antigen-detection ELISA, and virus isolation. Anal-
ysis of complete genome sequencing of the above
virus had 99.3% identity to the Gulu SUDV – 2000 virus.
The circumstantial evidence suggests that a bat was
the source of infection (Shoemaker et al. 2012).
In order to detect VHFs in Uganda, a surveillance
program was initiated in 2010 by the CDC, Atlanta,
USA, in collaboration with the Uganda Virus Research
Institute and the Uganda Ministry of Health (MacNeil
et al. 2011). Samples collected from the outbreak of
Kibaale, Uganda between July and August 2012,
yielded 11 laboratory confirmed cases (SUDV infection)
with 4 deaths (CFR 36%). Complete genome analysis of
the above four clinical samples showed »99.9%
sequence identity with each other and»99.2% identity
with the SUDV Nakisimata (Uganda – 2011), and SUDV
Gulu (Uganda – 2000) isolates (Albarino et al. 2013). In
the same surveillance, the samples collected from an
outbreak in the relatively close districts of Luwero,
Jinja, and Nakasongola, Uganda in November 2012
yielded six laboratory confirmed cases with three
deaths (CFR 50%). Sequence analysis of NP gene from
three serum samples revealed that they are nearly
»100% identical. Involvement of bats was suspected
for its transmission (Albari~no et al. 2013).
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2.2.3. Reston ebolavirus (Reston virus – RESTV)
In October 1989, 100 cynomolgus monkeys (Macaca
fascicularis) were transported from Manila, the Philip-
pines to Reston, Virginia and placed in a quarantine
facility. During the quarantine, numerous macaques
died, due to concomitant infection of Ebola-related
filovirus (as per the recent classification – Reston virus
or RESTV) and by simian hemorrhagic fever virus (SHFV
– an arterivirus) (CDC 1989). RESTV could be isolated at
least from five monkeys (Jahrling et al. 1990). This was
considered as the first known EBOV outbreak that
occurred outside of Africa as well as in non-human pri-
mates (Miranda & Miranda 2011).
Between November 1989 and March 1990, active
infection of RESTV occurred in seven shipments of cyn-
omolgus monkeys and further transmission to mon-
keys in quarantine facilities and many of them died.
Four animal handlers at a quarantine facility had anti-
RESTV antibodies (CDC 1989; Jahrling et al. 1990; CDC
1990a). Among these four cases, viremia developed in
one person on days 9, 10, and 11 post-inoculation
(WHO 2009). CDC has screened »2200 serum samples
from different monkey species from a variety of set-
tings, and »10% had antibodies against at least one of
four filovirus test antigens (EBOV, SUDV, RESTV, and
Marburg virus) (CDC 1990b).
Studies were initiated to document transmission at
export facilities located in the Philippines. At one
export facility, within three months period (between
March and May 1990), out of 403 monkeys, 161 (40%)
died from RESTV as confirmed in these animals. The
clinical manifestations observed in the outbreak
included diarrhea (50%), respiratory illness (34%), and
hemorrhage (1%) (Hayes et al. 1992). However, three
workers in the animal facility developed antibodies
against RESTV without any clinical signs (Miranda et al.
1991). The source of RESTV was not known (Rollin et al.
1999).
The next outbreak occurred in 1992. A batch of 55
cynomolgus monkeys was imported from a monkey-
breeding company in the Philippines into Italy in
March 1992. Four monkeys died within a month, and
viruses isolated from three monkeys were confirmed
as filoviruses by electron microscopy. They were shown
to be antigenically related to EBOV by indirect immu-
nofluorescence assay (WHO 1992). Although two peo-
ple developed virus-specific IgG antibodies, clinical
infections not observed (Miranda & Miranda 2011).
In March 1996, an imported cynomolgus monkey
that was held in a quarantine facility in Texas devel-
oped non-specific signs such as anorexia and lethargy
and died after three days. A second monkey also
showed similar kind of symptoms, and it was eutha-
nized. RESTV was isolated from both the animals. No
viral antigen or RESTV-specific antibodies could be
detected from animal handlers. Also, during the labora-
tory investigation, as in 1989 and 1990, SHFV could
have infected some of the animals (Rollin et al. 1999).
GP gene of RESTV isolated from the first animal had
98.9% nucleotide identity with the 1989 RESTV (San-
chez et al. 1999). In a USA–Philippine Joint Investiga-
tion at the monkey export facility in the Philippines it
revealed that 14 out of 21 animal houses had infected
monkeys. Anti-RESTV antibodies and virus nucleic acid
could be detected from 3 out of 1732, and 132 of 1011
monkeys, respectively. Seroprevalence on animal han-
dlers from monkey facilities and people with occupa-
tional exposure to pigs in USA, Italy, and the
Philippines, from 1989 to 2009 indicated that 9 (2%)
out of 662 persons had detectable RSTV-specific IgG
antibodies (Rollin et al. 1999; WHO 2009; Miranda &
Miranda 2011).
In the Philippines, during 2008–2009, serum sam-
ples were collected from 141 wild-caught bats (17 spe-
cies) and at different locations 7 out of 16 serum
samples from Rousettus amplexicaudatus bats had anti-
RESTV antibodies. These antibody-positive bats were
captured near the RESTV positive cynomolgus mon-
keys and swine suggesting that bats are a possible nat-
ural reservoir of RESTV (Taniguchi et al. 2011). In the
Philippines, between July 2007 and June 2008, there
were multiple outbreaks of a respiratory and abortion
disease syndrome in swine. The clinical signs resem-
bled an infection caused by a highly pathogenic por-
cine reproductive and respiratory syndrome virus
(PRRSV – an arterivirus), also referred to as ‘blue ear dis-
ease.’ The diagnostic investigation carried out at two
USA laboratories (APHIS and FADDL), revealed con-
comitant infection of pigs with PRRSV and RESTV. Viral
genomes from three samples revealed a very high
inter-isolate divergence (3.93%) as compared to the
original 1989 RESTV (2.5%). Anti-RESTV antibodies
could be detected in 6 out of 141 people who worked
on pig farms or with swine products (WHO 2009; Bar-
rette et al. 2009).
In a multi-institutional study on bats in the Philip-
pines, RESTV RNA was detected in oropharyngeal
swabs taken from Miniopterus schreibersii, and
sequencing of three samples showed high nucleotide
identity with a pig isolate from Bulacan province. Also,
four sera showed the presence of anti-EBOV antibod-
ies, i.e. three from Acerodon jubatus, and one from Pter-
opus vampyrus (possibly infected with EBOV and
RESTV), also suggesting that bats could be a natural
reservoir for RESTV (Jayme et al. 2015).
In China, between February and September 2011,
137 PRRSV confirmed pig spleen samples were
screened for the presence of RESTV, and four samples
were found positive. The partial sequencing of L gene
from four samples showed 95.1%–97.2% nucleotide
identities with each other and 96.1%–98.9% identity
with two RESTV variants of domestic pigs and cyno-
molgus macaques from the Philippines (Pan et al.
2014).
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2.2.4. Ta€ı Forest ebolavirus (Ta€ı Forest virus –
TAFV) and Bundibugyo ebolavirus (Bundibugyo
virus – BDBV)
There was a single non-fatal human case of Ta€ı Forest
virus (TAFV – previously known as Côte d'Ivoire ebola-
virus). In 1994, a Swiss ethnologist became infected by
TAFV after conducting an autopsy examination on a
wild chimpanzee in the Ta€ı Forest, Cote-d'Ivoire (Le
Guenno et al. 1995).
The first outbreak of VHF due to Bundibugyo virus –
BDBV (Bundibugyo ebolavirus) occurred in Uganda
between August and December 2007 and infested 131
cases with 42 deaths (CFR 32%) (MacNeil et al. 2011).
The entire genome sequencing of BDBV and the TAFV
were carried out by the Next Generation Sequencing,
and the analysis revealed that the BDBV differs signifi-
cantly from the other four Ebola virus species (Towner
et al. 2008). Another outbreak of BDBV occurred in Isiro,
DRC between June and November 2012 with 36 cases
with 13 deaths (CFR 36%). The full genome sequence
analysis revealed that the new BDBV was »98.6% iden-
tical to those of the original BDBV-2007 isolate
(Albari~no et al. 2013).
Human outbreaks of EVD are hypothesized to be
originated from direct contact with an infected animal
or its body fluids. The human-to-human transmission
occurred through the direct contact with blood from
infected patients or other body fluids (Report of an
International Commission 1978; Baron et al. 1983; Dow-
ell et al. 1999; Muyembe-Tamfum et al. 1999; Roels
et al. 1999; Francesconi et al. 2003; Muyembe-Tamfum
et al. 2012; Lawrence et al. 2017). The major risk factors
associated with virus transmission chains are gathering
funerals of Ebola positive patients, close contact with
family members of infected patients, and treating
patients without adequate personal protective meas-
ures (Okware et al. 2002). People visiting or taking care
of infected persons are at high risk of Ebola infections
(Muyembe-Tamfum et al. 2012). Recently, a post-recov-
ery sexual transmission of EBOV via semen has been
documented in the West African outbreak (Mate et al.
2015). Food can contribute to EBOV transmission, par-
ticularly through harvesting of bush meat (meat of
wildlife) (Mann et al. 2015). Transmission through
fomites in a clinical setting is unlikely (Bausch et al.
2007). The experimental aerosol transmission has been
demonstrated between monkeys (Jaxx et al. 1995;
Johnson et al. 1995; Reed et al. 2011) and from pigs to
monkeys (Weingartl et al. 2012). Similarly, airborne
transmission among humans is hypothetical (Baron
et al. 1983; Dowell et al. 1999).
3. Host range, carriers, and reservoirs
EBOV causes acute hemorrhagic fever in human and
non-human primates like cynomolgus (Macaca fascicu-
laris) and rhesus monkeys (Macaca rhesus), African
green monkey (Cercopithecus aethiops) and baboons
(Papio hamadryas). Inoculation of infected material to
laboratory animals had resulted in non-lethal febrile
disease, and subsequent passages of splenic material
in animals increase the virulence leading to the death
of laboratory animals. Among mice, the newborn is
more sensitive than adult ones. Stray dogs in Africa
eating animals died due to EBOV remained asymptom-
atic. Furthermore, a survey in 2005 showed that around
30% of dogs had seropositivity for EBOV without any
clinical signs (Allela et al. 2005; Osterholm et al. 2015).
Pigs have been shown to acquire natural EBOV infec-
tion and can transmit EBOV to humans (Osterholm
et al. 2015) and hence alarming the food safety and
animal health officials (Feldmann & Feldmann 2014).
However, limited information is available to predict or
prove the role of other livestock species, like cattle,
horse, sheep, etc. being a reservoir of EBOV (Mann
et al. 2015). Apart from the transmission of the virus
from reservoir animals, contaminated plant food prod-
ucts may also act as a source of infection to the suscep-
tible population (Mann et al. 2015).
Researchers predict that there may be a reservoir
host for EVD, as it has a re-emerging pattern and
hypothesize that three fruit bat species, namely Epo-
mops franqueti, Hypsignathus monstrosus, and Myonyc-
teris torquata are the important reservoir (Leroy et al.
2009). The African fruit bats have been suggested to
be the natural reservoirs for EBOV (Zaire) and Marburg
virus (Leroy et al. 2005; Barrette et al. 2009; Pourrut
et al. 2009). In the Philippines, anti-RESTV antibody
could be detected from bats which were captured near
to the area where RESTV infections in cynomolgus
monkeys and swine had been detected, suggesting
that bats could be the possible natural reservoir (Tani-
guchi et al. 2011; Jayme et al. 2015). Finding of EBOV
antibodies in bats from Bangladesh increased the spec-
ulation of the bat as a reservoir (Olival et al. 2013). In
humans, there is no age and sex difference in suscepti-
bility to EVD, and additionally, there is no report about
humans to act as a reservoir. Recently, a study con-
ducted to find any difference in the disease pathology
between male and female man showed both had simi-
lar risk rate, yet females have higher survival rate after
developing the disease (Team 2016). The virus can per-
sist in the semen of men for a period of several months
(»18 months) after recovery and can be transmitted to
the female (Heeney 2015; Mackay & Arden 2015;
Bausch and Crozier 2016; Fallah et al. 2016) which sug-
gests that man may be a reservoir for the EBOV. To
tackle this, WHO has recommended testing of semen
by RT-PCR from EVD survivors for three months from
onset of the disease along with counseling to encour-
age safe sexual practices until their semen is tested
negative twice (Check 2016; Purpura et al. 2016). Death
among chimpanzees and gorillas was always inter-
posed with outbreaks in man, dead non-human
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primate's contact, and also eating of fruit bats
(Muyembe-Tamfum et al. 2012). Direct contact with
secretions from infected persons and organ transplan-
tation seems to be another important means of trans-
mission. Body secretions from non-human primates
also act as a potential source of infection to man (Feld-
mann & Feldmann 2014). Mucous membranes seem to
be the major portal of entry of the organism. Aerosol
infection in non-human primates raises concern about
the chances of airborne infection in humans (Olival
et al. 2013). Research findings show that the dried virus
particle can travel longer distance compared to the
virus in fluid form. EBOV needs a liquid medium for its
survival. Hence, its transmission cannot be airborne.
Studies reported that due to the increase in population
and also increased movement of man and animals
there is difference in the disease dynamics of recent
outbreaks of EVD as compared to earlier outbreaks
(Pigott et al. 2014).
3.1. Role of animals in transmission of EBOVs
The possible source and mode of transmission of EBOV
for each outbreak are described earlier in the section
on epidemiology. In this section, the role of animals in
the transmission of EBOV is highlighted. Regarding the
multiple outbreaks of EBOV between 2001 and 2003 in
Gabon and RC, there is a link to handling/eating of
bush meat. The majority of outbreaks started with the
history of handling of infected wild animal carcasses,
including gorillas, chimpanzees, duikers (small ante-
lopes), and possibly monkeys by the index cases (WHO
2003; Leroy et al. 2004).
In 1994, in the Ta€ı National Park, Côte d'Ivoire an
Ebola outbreak occurred among chimpanzees (For-
menty, Boesch, et al. 1999), and an ethologist was
infected with TAFV while conducting a necropsy on a
wild chimpanzee (Formenty, Hatz, et al. 1999). Investi-
gation of a 2007 EBOV outbreak suggested that the
possible source was fruit bats (Leroy et al. 2009). Since
anti-EBOV antibodies and viral RNA have been
detected in bats, there is a strong belief in the research
community that fruit bats could be a primary natural
reservoir for EBOV (Pourrut et al. 2009). In a large-scale
survey conducted at Gabon and RC between 2003 and
2008, anti-EBOV antibodies could be detected from six
bat species (Pourrut et al. 2009).
Multiple outbreaks of RESTV occurred between 1989
and 1996 in captive monkeys in the Philippines, the
United States of America, and Italy. During these out-
breaks, three animal handlers developed anti-RESTV
antibodies without clinical symptoms. One became
infected during necropsy on a monkey as evidenced
by viremia and seroconversion. An additional, five
monkey handlers in the Philippines developed anti-
RESTV antibodies without significant illness (Miranda &
Miranda 2011). Serological studies on animal handlers
from monkey facilities and people with occupational
exposure to pigs in the USA, Italy, and the Philippines,
from 1989 to 2009 indicated that 9 (2%) out of 662 per-
sons had detectable RSTV-specific IgG antibodies
(Rollin et al. 1999; WHO 2009; Miranda & Miranda
2011).
The RESTV infection was also identified in the Philip-
pines (2007–2008) and China (2011) along with co-
infection of PRRSV (Barrette et al. 2009; Pan et al. 2014).
In the Philippines, six workers in contact with infected
pigs had anti-RESTV IgG antibodies, suggesting that
pigs can transmit RESTV to humans. Transmission from
pigs may be due to direct contact with body fluids and
respiratory routes (WHO 2009). Serum samples from
wild-caught bats during 2008–2009 in the Philippines
revealed anti-RESTV antibodies in R. amplexicaudatus
bats. These antibody-positive bats were captured near
to the area where REST infections were detected in
cynomolgus monkeys and swine (Taniguchi et al.
2011). In another study, RESTV RNA was detected in
oropharangeal swabs taken from Miniopterus schreiber-
sii, and the presence of the virus had also been identi-
fied in additional sympatric taxa (Miniopetrus australis,
Cynopterus brachyotis, and Chaerephon plicata) and
additional locations (Puning Cave). Also, the presence
of anti-RESTV antibodies was confirmed from Acerodon
jubatus and Pteropus vampyrus suggesting that RESTV
infection is widespread in bats (Jayme et al. 2015).
In a seroprevalence study conducted in the dog
population during 2001–2002 outbreaks in Gabon,
anti-EBOV virus antibodies could be detected from a
significant number of samples which were collected
from the human outbreak area. However, antibodies
were detected in 2 out of 102 dog samples which were
collected from the non-exposed country (Allela et al.
2005). Neither Ebola-like illness nor virus could be iden-
tified from dogs, and the validity of the immune assay
for canine samples has been questioned (Osterholm
et al. 2015). During ecological studies in the CAR in
1998, EBOV RNA could be detected from mice (Mus
setulosus and Praomys spp.) and a shrew (Sylvisorex
ollula) (Morvan et al. 1999).
3.2. Role of plants and food materials in
transmission of EBOVs
Apart from the transmission of the virus from reservoir
animals and contaminated meat, plant food products
may also act as a source of infection to the susceptible
population (Mann et al. 2015). A two-year-old child was
identified as index case who was playing with man-
goes partially eaten and dropped by bats (Coen &
Henk, 2015; Mann et al. 2015). There are also reports of
cases of Ebola infection and diseases acquired by eat-
ing fruits half-eaten by bats (Leroy et al. 2007). This
may be due to the shedding of virus in the saliva of
bats (Amman et al. 2015). It is evident from the study
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conducted in which plants experimentally inoculated
with the virus supported the replication of virus with
or without the development of visible lesions (Swane-
poel et al. 1996; Okware et al. 2002). The first victim of
2007 outbreak in the DRC was known to purchase fresh
bat meat before developing the disease (Mann et al.
2015). But contradictory opinion occurs regarding the
role of bushmeat as a source of infection (Mufunda
et al. 2016). There is only indirect evidence available in
this regard, and more needs to be investigated to con-
firm whether plants, plant products, and other food
material can contribute towards spreading the disease.
If this is so, then it is a serious concern as it would
make the disease control more difficult. Furthermore,
there is also fear that it might act as a weapon for bio-
terrorism (Maras & Miranda 2016). Capacity to transmit
the infection through food products depends on the
ability of the virus to survive in the atmosphere for a
certain period. It has been found that EBOV can survive
up to a period of three weeks at a lower temperature
in the atmosphere (Piercy et al. 2010).
4. Ebola virus disease (EVD)
EVD has an acute clinical outcome with signs like nau-
sea, vomiting, diarrhea, pain in the abdomen, muscles,
and head; there is also the loss of appetite and enlarge-
ment of lymph nodes (Olival et al. 2013; Feldmann &
Feldmann 2014). The incubation period ranges from 1
to 10 days, while exceptions may reach up to 21 days.
Hemorrhages and sudden rise in temperature are the
two common clinical signs noticed and other signs of
chest pain, difficulty in breathing and swallowing.
Blood may be noticed in feces and urine; there may
also be coagulation problem during bruises or damage
to blood vessels (Jahromi & Mood 2015). Bleeding
from nostrils, gums, vaginal mucosa, and gastrointesti-
nal (GI) tract have been a common sign in 40%–50% of
the cases, and maculopapular rashes can be noticed in
50% of cases. Bleeding begins within seven days from
the start of initial clinical symptoms, and it may be
noticed both internally as well as subcutaneously.
Hemorrhages may range from petechiae, purpura, and
ecchymoses; hematomas can also occur due to bleed-
ing in the subcutaneous tissue. Death can occur within
7–16 days from the start of clinical symptoms and
occurs due to several organ dysfunctions and severe
bleeding (Takada & Kawaoka 2001; Hoenen et al.
2006). Patients who survive from EVD will exhibit organ
swelling, orchitis, and pain in the joints. An overview of
EBOV transmission, pathogenesis, and clinical signs is
depicted in Figure 5.
Figure 5. Transmission, pathogenesis, and clinical signs of Ebola virus.
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The major route of infection is through the mucosa
or skin from where it reaches the macrophages, mono-
cytes, and dendritic cells, leading to spread of the virus
to regional lymph nodes, liver, and spleen. Macro-
phages and monocytes stimulated by EBOV release
cytokine storm thereby damaging tissues and blood
vessels (Olival et al. 2013). Death occurs due to blood
loss and/or coagulation (Casillas et al. 2003). Coagulop-
athy occurs due to thrombocytopenia, loss of anticoag-
ulant protein C, destruction of clotting factors, and also
due to the destruction of fibrin. Damage to blood ves-
sels causes disseminated intravascular coagulation as
well as renal failure (Geisbert et al. 2003a; Nyamathi
et al. 2003). Antibodies developed against EBOV bind
with the complement C1q and reach to the binding
sites on dendritic cells and macrophages, leading to
damage of these cells.
Lesions of EVD include extensive hemorrhages of
the mucosa, necrosis of different organs like liver, kid-
ney, testes, and ovaries. Necrotic foci with inflamma-
tory cells can be noticed in hepatic lobules, and there
may be multinucleated syncytia formation in the
hepatic cells. Necrosis of red pulp and fibrin deposition
are the characteristic lesions noticed in the spleen.
Splenic macrophages reveal big, acidophilic particles
in their cytoplasm which are similar to intracytoplasmic
inclusion bodies. GI tract shows mononuclear infiltra-
tion into the submucosa and lamina propria. Mild
emphysema, edema in the terminal alveoli, and stasis
of blood can be noticed in the lung parenchyma
(Wyers et al. 1999).
The clinical features observed in different EBOV and
SUDV outbreaks were almost similar. The disease
caused by EBOV and SUDV is known as ‘Ebola virus dis-
ease’ (EVD) – the term ‘Ebola hemorrhagic fever’ (EHF)
was previously used. In EBOV outbreak in Zaire in 1976,
the major clinical manifestations observed included a
severe sore throat, maculopapular rash, intractable
abdominal pain, and bleeding from multiple sites prin-
cipally the gastrointestinal tract (malena, haemateme-
sis, mouth/gingival, vaginal epistaxis, injection sites/
scarification) (Report of an International Commission
1978). More detailed clinical manifestations were
reported in SUDV outbreaks in Sudan in 1976. In this
outbreak, EHF was a unique clinical disease with a CFR
(53%) and a prolonged recovery period in those who
survived. The clinical signs observed were fever, head-
ache, and pains in joint and muscle, diarrhea, vomiting,
chest pain, pain and dryness of the throat, rash, and
hemorrhages (Report of a WHO/International Study
Team 1978). In contrast to the above outbreaks, clinical
manifestations observed in 2013–2016 West African
outbreaks differed mainly due to less hemorrhage (less
than 5% of patients before death). There were four clin-
ical phases: (1) an early febrile phase (onset 0–3 days) –
fever (up to 40 C), malaise, fatigue, body aches etc., (2)
gastrointestinal phase (onset 3–10 days) – epigastric
pain, nausea, vomiting, diarrhea, persistent fever,
asthenia, headache, conjunctival injection, chest pain,
abdominal pain, arthralgias, myalgias, hiccups, delirium
etc., (3) shock or recovery phase (onset 7–12 days)
diminished consciousness or coma, rapid thready
pulse, oliguria, anuria and tachypnea, and (4) late com-
plications phase (onset 10 days) associated with gas-
trointestinal hemorrhage, secondary infections,
meningoencephalitis, and persistent neurocognitive
abnormalities (Chertow et al. 2014; Chertow et al.
2016). The convalescent state is complicated by uveitis
and viral shedding through ocular discharge (Varkey
et al. 2015; Chancellor et al. 2016). In a study conducted
by the WHO on EVD in West Africa, the most common
symptoms observed included fever, fatigue, vomition,
diarrhea, loss of appetite, headache, abdominal pain,
and hemorrhagic symptoms (WHO Ebola Response
Team 2014, 2016).
5. Post-Ebola syndrome
Of note, thousands of patients have survived during
the Ebola outbreaks and have shown symptoms that
persisted or developed after hospital discharge, which
could be due to the persistence of the virus in the
immune privileged sites, such as brain and retina of
the host (Fallah et al. 2016). Defective interfering par-
ticles of the virus might be responsible for virus persis-
tence and chronic condition due to EBOV infection as
observed under in vitro condition in cell culture condi-
tion (Calain et al. 2016). To note, this virus persists in
the body longer than suspected by the scientists. How-
ever, there is a paucity of sequelae of data regarding
post-Ebola syndrome (PES). In an SUDV outbreak in
Uganda in 2000, 60 out of 257 people survived and the
PES complications observed included abdominal pain,
loss of vision and hearing, impotence, bleeding, psy-
chological problems, and general weakness (Wendo
2001; Shantha et al. 2016). During 1995 EBOV outbreak
in Kikwit DRC, the clinical signs observed among 19
survivors were arthralgia, ocular disease, parotitis, uni-
lateral orchitis, hearing loss or tinnitus, and pericarditis
(Kibadi et al. 1999). In the same outbreak, 29 Ebola con-
valescents and 152 household contacts (HHCs) were
monitored for up to 21 months. Arthralgias and myal-
gia were the most commonly reported symptoms
among convalescents. The other clinical signs
observed during the first six months of follow-up were
abdominal pain, extreme fatigue, and anorexia more
frequently than did HHCs, whereas fever, headache,
diarrhea, dyspnea, hiccups, and hemorrhage were the
same in both groups (Figure 5) (Rowe et al. 1999).
In a recent outbreak occurred in Guniea in 2015, a
survey was conducted on 105 EVD survivors using a
standard data collection form revealing anorexia and
arthralgia frequently (Qureshi et al. 2015). Other clinical
signs reported in different outbreaks included pain,
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weakness, hearing difficulty, and mental disturbances
(Report of a WHO/International Study Team 1978;
Okware et al. 2002). Recently, a very systematic cross-
sectional survey of the symptoms of all survivors was
conducted from the Ebola Treatment Unit at Freetown,
Sierra Leone. The unit treated 88 EVD confirmed cases
between 1 December 2014 and 31 March 2015, of
whom 44 survived. The symptoms observed in the sur-
vivors included musculoskeletal pain (70%), headache
(48%), and ocular problems (14%). A total of 117 sepa-
rate complaints were reported, 31 patients (70%) had
musculoskeletal pain, 21 (48%) had headaches, and 6
(14%) had ocular problems. Twenty-six (59%) of the 44
survivors reported other symptoms like cough, abdom-
inal pain, chest pain, itching, insomnia, fever, loss of
appetite, labored speech, epigastric pain, rash, weight
loss, hiccups, increased appetite, chest pain, sneezing,
diarrhea, vomiting, left sided weakness with facial
nerve palsy, breathlessness, rash, dry flaky skin, ear-
ache, fever blister/cold sore, left scrotal swelling, nasal
congestion, and tremors (Scott et al. 2016).
6. Pathogenesis
The EBOV viral proteins are involved in various stages
of the pathogenesis (Figure 5), namely VP35 is essential
for ribonucleoprotein complex (RNP) production,
important for viral replication and transcription, and
VP35 blocks the signaling of type I interferon (Muhl-
berger et al. 1999; Basler et al. 2000; Basler et al. 2003).
By antagonizing the production of interferon, host cel-
lular IFN-a/b response obstruction and inhibition of
anti-viral protein production as a result of dsRNA of the
virus are the mechanisms involved in pathogenesis
caused by VP35 protein (Basler et al. 2003; Wong et al.
2014). VP40 matrix protein is involved in budding from
the host cell and also involved in the formation of the
virus-like particles (VLPs) (Harty et al. 2000; Jasenosky
et al. 2001; Noda et al. 2002). Envelope GP and other
viral proteins may have a role to inhibit immune mech-
anism thereby increasing the virulence of the virus
(Takada & Kawaoka 2001). Lately, scientists have tried
to elucidate the exact molecular pathogenesis of this
virus (Shi & Shen 2013) where they found that caspase
8, FADD like apoptosis regulator (CFLAR), dystroglycan
1 (DAG1), and tissue factor pathway inhibitor were
inhibited in human umbilical vein endothelial cells
expressing EBOV GP.
The virus enters through mucosal surfaces, cut or
lesions of the skin, or direct transfer. Cells like mono-
cytes, macrophages, dendritic cells, hepatocytes, and
endothelial cells are the targets of EBOV (Feldmann
et al. 1996; El Sayed et al. 2016). Epithelial, endothelial
fibroblasts, hepatocytes, and adrenal gland cells are
also infected (Olejnik et al. 2011). Following infection,
mononucleated cells are preferred by EBOV for replica-
tion in initial stages and a rapid viremia is generated
(Olejnik et al. 2011). EBOV destructs lymphocytes and
monocytes and induces cytokine storm and coagula-
tion anomalies. Also enhanced activation of B and T
cell is evident with a higher magnitude of inflamma-
tory cytokines (McElroy et al. 2015). Evidence suggests
the pathological manifestations by EBOV via releasing
immune mediators which are more critical. There is a
rapid multiplication of virus inside the host, and it
escapes the host defense mechanism. A major target
of EBOV is antigen presenting cells mainly CD16+
monocytes which are not activated in an acute episode
of EVD (L€udtke et al. 2016). Both virus-encoded and
host proteins are responsible for pathogenesis, releas-
ing inflammatory cytokines like tumor necrosis factor
alpha (TNF-a), IFN-a, IFN-g , interleukin-2 (IL-2), and IL-
10 that are responsible for massive hemorrhage and
death (Villinger et al. 1999). This strongly activates the
immune system, and mainly interferon-related genes
are upregulated (such as ISG15, OAS1, etc.) (Caballero
et al. 2016). Antibodies can be detected after six days’
post infection and can be detected up to 90 days.
Reports show that IgG response can be detected for
around 400 days in animals while it can persist around
10 years in human sera (Ksiazek, Rollin, et al. 1999).
Though antibodies can be detected in the serum
against glycoproteins, they turned out to be not pro-
tective against infection and also failed to inhibit repli-
cation of the virus in cell culture. Passive
administration of antibodies to animals prevented clin-
ical manifestations but has not prevented death which
hypothesizes that immunity is not mainly through anti-
bodies but could also be cell-mediated. There is no
report till to date regarding the re-infection of EBOV in
a person who suffered earlier infection, showing that
there is lifelong immunity against EBOV.
During the clinical course, the predominant clinico-
pathological findings included hypoalbuminemia,
hyponatremia, hypokalemia, hypocalcemia, and hypo-
magnesemia. Aminotransferase activity peaked at a
median of nine days after the onset of illness (Uyeki
et al. 2016).
7. Experimental animal inoculation
Several experimental studies have been conducted on
the animal-to-animal EBOV transmission using differ-
ent animal species. One of the studies demonstrated
transmission of EBOV from inoculated rhesus monkeys
to control monkeys caged in the same room. They pos-
tulate the possible mode of transmission through aero-
sol, oral, or conjunctival exposure to virus-laden
droplets (Jaax et al. 1995). However, there is a possibil-
ity for transmission through spitting and throwing
feces by the monkeys (http://www.cdc.gov/vhf/ebola/
transmission/human-transmission.html) or through
routine animal husbandry practices (Osterholm et al.
2015). In another study, the transmission of EBOV from
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infected pigs to uninoculated caged macaques was
demonstrated when they were housed together (Wein-
gartl et al. 2012). The route of inoculation also might
play an important role in the transmission as in an
experiment when monkeys were inoculated with EBOV
via intramuscular route; no transmission occurred in
uninoculated control monkeys (Alimonti et al. 2014).
Few studies have examined the role of route of
exposures in transmission. One such study demon-
strates that EBOV infection through oral, conjunctival,
or intramuscular routes can cause the illness in rhesus
monkeys (Jaax et al. 1996). In another study, aerogenic
route of infection was demonstrated with different
doses of antigen (Johnson et al. 1995). Another study
investigated the replication, pathogenicity, shedding,
and transmission efficacy of EBOV in pigs, wherein, fol-
lowing mucosal exposure, EBOV replicated in pigs,
mainly in the respiratory tract, and induced severe
lung lesions (Kobinger et al. 2011).
8. Clinical and laboratory diagnosis: a complex
issue!
During several Ebola outbreaks since 1976, EVD has
emerged as a direct challenge to manage (CDC 2015;
Mattia et al. 2016; Racsa et al. 2016). If detected early, it
gives good prognosis and lives can be saved (Okware
et al. 2015). The diagnostic and therapeutic advances
following the most recent outbreak have improved
prognosis to some extent (Butler 2014; Gilbert 2015). In
a September 2014 statement, the WHO said:
The Ebola epidemic ravaging parts of West Africa is the
most severe acute public health emergency seen in
modern times. Never before in recorded history has a
biosafety level four pathogen infected so many people
so quickly, over such a broad geographical area, for so
long. (WHO 2014)
This grim situation triggered a search for reliable
and sensitive laboratory tests to identify Ebola and
diagnose EVD as early as possible after exposure (Ayu-
kekbong 2016; Uyeki et al. 2016). Historically, Dr Ngoy
Mushola recorded the first clinical description of the
EVD in his clinical log during the Zaire outbreak: ‘The
illness is characterized by a high temperature of about
39 C, hematemesis, diarrhea with blood, retrosternal
abdominal pain, prostration with “heavy” articulations,
and rapid evolution of death after a mean of three
days’ (Olupot-Olupot 2015; Shah et al. 2015). At present
WHO/CDC defines that:
any illness with onset of fever and no response to
treatment for the usual causes of fever in the area,
along with at least one of the following signs: bloody
diarrhea, bleeding from gums, bleeding into skin (pur-
pura), and bleeding into the eyes and urine
for a suspected Ebola case.
To proceed for diagnosis, first of all, patients’ history
such as travel, occupation, and exposure to wild ani-
mals must be recorded. The most difficult task in EVD
exposure is to specifically and differentially diagnose
the EVD at the onset of disease symptoms. The EVD-
infected individuals are presented clinically as very sick
with muscular and abdominal pain, cramps and hic-
cups with vomition and diarrhea, severe headache,
weakness followed by bruising and petechial bleeding.
With the severity of disease, mucosal and frank bleed-
ing occurs in the form of epistaxis and bloody stool.
The EVD symptoms are quite similar with several other
infectious diseases such as Typhoid fever, Lassa fever,
Meningococcemia, Malaria, Influenza, Measles, Mar-
burg virus disease, Shigellosis, Leptospirosis, Yellow
fever, fulminant viral Hepatitis, and Travelers’ diarrhea
(Hartman et al. 2010; Uyeki et al. 2016) and thus need
to be differentially diagnosed. The CDC/WHO recom-
mend for immediate clinical risk analysis for EBOV
infection in any person with the symptoms described
above. Currently, there is no specific treatment existing
except that an early diagnosis of EBOV will ensure fast
supportive care before the development of irreversible
shock and necessary preventive measures and patient
isolation can be instituted. Since major Ebola outbreak
in 2014, researchers are tirelessly working to develop a
specific test to confirm Ebola exposure before and after
the onset of clinical symptoms. This initiative is also
critical as most of the body fluids are highly infectious
due to the persistent presence of Ebola for a long time.
The abrasions on the skin and exposed mucosa are the
most likely route of infection after direct contact of
EBOV-containing body fluids from an infected person.
The WHO/CDC characterized blood, feces, and vomit
as the most infectious body fluids. Furthermore, EBOV
also been detected in saliva (Formenty et al. 2006;
Spengler et al. 2015), breast milk (Nordenstedt et al.
2016), aqueous humor (Varkey et al. 2015), semen, vag-
inal fluid, and urine (Deen et al. 2015; Chughtai et al.
2016; Fischer et al. 2016; Pettitt et al. 2016; Thorson
et al. 2016).
After the EVD-outbreak in 2014, there is a critical
urgency for the availability of robust diagnostic and
prognostic tools for infectious diseases, particularly, in
the resource-poor areas (Ghani et al. 2015). Diagnostic
measures must be employed as soon as clinical symp-
toms become evident. In the early stage of infection,
the presence of EBOV-antigen must be confirmed, fol-
lowed by antibody detection at the late stage of infec-
tion (Olival et al. 2013; Okeke et al. 2014). In the year
1979, the first report on the quantitative measurement
of antibodies against EBOV in human sera from North-
west Zaire was published (Van der Groen & Pattyn
1979). Subsequently, an immunofluorescence focus
assay (Truant et al. 1983) and formalin-fixed tissue
specimens by enzyme treatment (Kurata et al. 1983)
were developed to detect EBOV. Since EBOV equally
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infect primates, an enzyme immunosorbent assay was
employed (Ksiazek et al. 1992) for the detection of
EBOV in the infected primate tissues. For rapid diagno-
sis (within 30 minutes), EBOV-antigen detection based
on the immune-filtration technique was also devel-
oped with limited detection of the Zaire and Sudan
species only (Lucht et al. 2007). Ultimately, the confir-
matory diagnosis relies on the isolation of virus on
Vero or Vero E6 cell lines (Steele et al. 2001; Sanchez
2007; Makino & Kawaoka 2009). However, handling of
infected samples and isolation of virus essentially
requires BSL 4 infrastructure due to very high infectiv-
ity and mortality of lab personel. Various other diag-
nostic platforms include electron microscopy,
immunohistochemistry, and IgG and IgM antigen cap-
ture enzyme-linked immunosorbent assay (ELISA) has
also been evaluated (Mishra 2014). Serum, plasma, and
whole blood have been used with good results for
detection of EBOV using antigen capture ELISA by
using a semi-synthetic repertoire of llama single-
domain antibodies (Sherwood et al. 2007).
RT-PCR seems to be a good diagnostic tool for
detection of the virus (Drosten et al. 2002; Towner
et al. 2004). Given the complex nature of EVD and rapid
transmission, it is essential to deploy highly sensitive
and specific EBOV detection assays. A reverse transcrip-
tion loop-mediated isothermal amplification (RT-LAMP)
has been developed to detect EBOV within 26 minutes
(Kurosaki et al. 2007) without RT-PCR instruments.
Recently, RT-LAMP for detecting EBOV directly from
blood has been described for the GP gene of EBOV. It
detects EBOV within 40 minutes with high sensitivity of
detection limit to identify 2.8 £ 102 pfu/test and 1 £
103 pfu/test of EBOV-Kikwit and EBOV-Makona, respec-
tively (Benzine et al. 2016). Further, using DNA-interca-
lating dye SYBR green based or TaqMan probe-based
real-time RT-PCR, highly sensitive detection of EBOV-
antigen is possible (Huang et al. 2012; Liu et al. 2012).
A multiplex real-time PCR has also been developed to
detect Ebola and Marburg viruses in a single step
(Yang et al. 2012). Similarly, several companies around
the world are marketing lateral flow-like kits that can
detect EBOV-antigens. Corgenix (Broomfield, CO, USA)
and Veda Lab (Alenson, France) have developed kits
which use a small amount of sample (blood, plasma, or
urine) from infected persons (Baker 2014).
ELISA tests can be used for detection of antibodies
of EBOV though this is not promising as antibodies
develop only in the late phase of the infection and a
chance for a person to escape the initial phase without
death is less (Ksiazek, West, et al. 1999; Mishra 2014).
Similarly, there is cross-reaction of antibodies with
other pathogens. Therefore, antibody detection tests
are less effective for EBOV infection. Specific detection
of EBOV in clinical laboratories is currently being car-
ried out largely through the analysis of the virus's
nucleic acid (genetic material), using commercial or in-
house tests (Dhama, Malik, et al. 2015). Although these
nucleic acid tests (NATs) are highly specific they require
well-established laboratories and fully trained person-
nel due to their complex nature. Also, the turn-around
time of the final results may take more than 12–
24 hours. During Guinea Ebola outbreak, patient's
swab samples were used to detect EBOV by a rapid
reverse transcription recombinase polymerase amplifi-
cation (RPA) assay (EBOV-RT-RPA). This highly efficient
assay produced results in 30–60 minutes (Faye et al.
2015; Dedkov et al. 2016). A new test comparable to
ELISA is developed by using Fe3O4 magnetic nanoparti-
cle as a nanozyme probe (nanozyme-strip) to specifi-
cally detect the EBOV-glycoprotein as low as 1 ng/mL
and is 100-fold more sensitive than the standard strip
method (Duan et al. 2015). The WHO/CDC has officially
approved (19 February 2015) the *ReEBOVTM Antigen
Rapid Test Kit (Corgenix, Broomfield, CO, USA) as eligi-
ble for procurement and to be used in Ebola-affected
countries (Dhillon et al. 2015; Flint et al. 2015). The
ReEBOVTM Antigen Rapid Test is an immune-chro-
matographic dipstick immunoassay point-of-care test
based on detection of the Ebola protein (VP40 antigen)
rather than nucleic acid and can provide results within
15 minutes. The ReEBOVTM Antigen Rapid Test kit can
correctly identify about 92% of Ebola-infected patients
and 85% of those not infected with the virus compared
to other available NAT and currently being used in the
field (RealStar® Filovirus Screen RT-PCR Kit 1.0, Altona
Diagnostics GmbH, Hamburg, Germany). Despite the
fact that ReEBOVTM Antigen Rapid Test kit is less accu-
rate, it is easy to perform and does not require electric-
ity. It can, therefore, be used at lower health care
facilities or in mobile units for patients in remote areas
(Broadhurst et al. 2015). It is always better to confirm
the data from ReEBOVTM Antigen Rapid Test Kit by test-
ing a new blood sample using an approved Ebola NAT.
To test the sensitivity and versatility, comparative stud-
ies on 11 different procedures have been performed
for currently available RT-PCR assays (Nouvellet et al.
2015; Cherpillod et al. 2016). However, the detection
limit of ReEBOVTM test is not sufficiently sensitive to
identify all the EVOB-suspected cases. Another signifi-
cant obstacle to the use of these RT-PCR tests is to
detect novel filovirus species and lineages which have
emerged due to rapid mutation rates and genetic
diversity of RNA viruses. More recently, a real-time RT-
PCR assay was developed as a point-of-care test that
does not require RNA extraction and thus the entire
process completes within 1.5 hours (Zhang et al. 2017).
The chronology of diagnostic tests developed to
detect EBOV in various situations has been summa-
rized in Table 3 and the diagnostic kits developed for
EBOV detection are presented in Table 4.
In recent times, new nucleic acid sequencing tech-
nologies (referred to as ‘next-generation’ sequencing
(NGS) have evolved which provide more efficient and
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Nucleic acid PCR-based diagnostic assay. Leroy et al.
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(8) Development and evaluation of a
fluorogenic 5' nuclease assay.
Cultured virus in Vero
cells
Glycoprotein (GP) antigens Detect and differentiate




(9) 5' nuclease probe detection by
real-time reverse transcription-
PCR.




(10) Antigen capture ELISA directed
against the envelope
glycoprotein of Ebola virus.
Serum Glycoprotein (GP) antigens Sensitivity up to »103 pfu/ml.




(11) Rapid diagnosis of Ebola
hemorrhagic fever by reverse
transcription-PCR in an outbreak
setting and assessment of
patient viral load as a predictor
of outcome.




(12) Immune-filtration based antigen-
detection assay for rapid
detection (only Zaire and Sudan
strain-specific).
Serum Matrix protein (VP40) Sensitivity similar to ELISA and
rapid assay without need of





amplification assay (Zaire strain-
specific).
Vero cells cultured virus NP Portable amplification-based
platform.
Negative for other febrile
disease viruses such as Lassa
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Liu et al. (2012,
2014)
(16) Multiplex RT-PCR for simultaneous
detection of Marburg virus and
Ebola virus.
Cell cultured virus Nucleic acid Sensitive with ability to test




(17) Indirect ELISA for detecting Abs
specific to Ebola and Marburg
viruses.
Cell culture supernatant NP Very sensitive assay. Huang et al.
(2014)
(18) Novel biomarker soluble CD40
ligand (sCD40L) correlates of EVD
clinical outcome.
Serum Different 26 cytokines Simultaneous detection of 26
proinflammatory cytokines.
Increased soluble CD40
ligand (sCD40L) level is
indicator of diseases severity.
McElroy et al.
(2014)
(19) Comprehensive multiplex one-step
TaqMan qRT-PCR assay.
Cell cultured virus Nucleic acid In a single qRT-PCR assay, 28




(20) Aptameric sensing technology for
rapid pandemic monitoring.







specific viral diagnostics. The technology of NGS pro-
vides rapid high-throughput DNA sequence data in
large volumes. The NGS has been successfully tested
for its efficiency during the 2014 Ebola outbreak in
Guinea and Sierra Leone (Gire et al. 2014). This study
was able to identify the virus sequence differences and
similarities to previous outbreak variants and to elabo-
rate its emergence from the natural reservoir. Further,
data helped the researchers to understand how EBOV
has moved across African nations during the months
of the outbreak (Gire et al. 2014). A new approach for
direct detection of EBOV infection has been tested.
This approach is amplification-free and based on the
optofluidic analysis (Cai et al. 2015). Recently, a
research team from Marburg, Germany (Kr€ahling et al.
2016), has developed a Zaire Ebola virus (ZEBOV)-spe-
cific ELISA using inactivated ZEBOV-Makona virus iso-
late. The ZEBOV-ELISA is highly specific and sensitive
with superior reproducibility. This newly developed
test is suitable both for the detection of the ZEBOV sur-
face glycoprotein in vaccinated individuals and for
detection of specific antibody responses directed
against different ZEBOV proteins in EVD patients
(Kr€ahling et. al. 2016). The possibility of EBOV-encoded
miRNA-like fragment as a specific biomarker for early
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(21) GeoSentinel surveillance network.
Differential diagnosis of illness in
travelers arriving from Sierra












(22) Antigen capture ELISA and lateral
flow immunodiagnostic.
Serum Matrix VP40 and glycoprotein
(GP) antigens




(23) Optofluidic analysis system for
amplification-free, direct
detection of Ebola.
Serum Nucleic acid Chip-scale approach
Single nucleic acid detection
in 10 minutes.
Cai et al. (2015)
(24) Fe3O4 magnetic nanoparticle-
based immuno-chromatographic
strip (Nanozyme-strip)




(25) Rapid recombinase polymerase
amplification Ebola virus
detection assay.
Serum and swab Nucleic acid Assay can combine extraction




(26) Real-time EBOV-L-RT-qPCR for
detection of Zaire Ebola virus.
Serum or blood L gene No false positives with serum
or EDTA bloods samples.
J€a€askel€ainen
et al. (2015)
(27) The Ebola Spatial Care PathTM
(SCP): accelerating point-of-care
testing (POCT).
Whole blood Platelet count, white blood
cell count, granulocyte




specific IgM and IgG,
hemoglobin and hematocrit
Ebola molecular diagnostics








(28) Ultrafast, sensitive and large-
volume on-chip real-time PCR.
(General pathogen detection) Ultrafast RT-PCR system using
microfluidic thermalization








GP and NP gene No cross-reactivity.






Cultured virus Untranscribed trailer region
or nucleoprotein coding
region of the viral RNA
Higher sensitivity to nanoscale.











Detection up to pico-mole
level.








– Whole blood may be used. Leski et al.
(2015); Weller
et al. (2016)
(33) Zaire Ebola virus (ZEBOV)-specific
enzyme-linked immunosorbent
assay (ELISA) using inactivated
ZEBOV isolate Makona
Serum Glycoprotein (GP) antigens Simple and cost effective. Kr€ahling et al.
(2016)
(34) RT-LAMP Blood Untranscribed trailer region
or nucleoprotein coding
region of the viral RNA.
Whole blood used to detect GP
gene of EBOV
high sensitivity





(35) ReEBOV Antigen Rapid Test
(ReEBOV RDT)
Whole blood or serum VP antigen (anti-EBOV VP40) Highly specific
Point of care test for EVD
Cross et al.
(2016)
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2016). The high potential of the recent advances in the
field of diagnosis including molecular tools, LAMP, lat-
eral flow assay, biosensors, biochips, microarrays,
recombinant protein, and nanotechnology-based
detection methodologies must be exploited to their
full perspectives for rapid detection and monitoring of
EBOV infections (Kurosaki et al. 2007; Belak et al. 2009;
Dhama et al. 2014; Benzine et al.2016).
9. Global EBOV monitoring and disease
surveillance: did we learn new lessons?
Due to social conflicts, globalization and climate
change, intercontinental migration of humans has
been rampant. The uncontrolled movements and
demographic transitions demand a serious prepared-
ness for unseen lethal epidemics of uncommon viral
diseases. It is no more an exotic infection for any coun-
try but has taken the nature of a global problem
(Arwady et al. 2015). Thus, surveillance of emerging
infectious diseases is extremely vital for the early iden-
tification and preparedness of public health threats.
Fortunately, particularly after the 2014 outbreak, sev-
eral new rapid molecular diagnostic assays have
become available for precise surveillance of highly
infectious diseases in real-time manner (Benowitz et al.
2014; Curran et al. 2016).
The last EBOV outbreak in West Africa is a serious
warning to the public health system and awakening to
the communities for better preparedness to combat
such large-scale epidemic. More than 12,000 deaths
were reported during 2014 EBOV-epidemics. The EBOV
and related viruses are extremely lethal and managing
such diseases is beyond our capacity if not prepared
(Walker & Whitty 2015; Woolhouse et al. 2015; Jacob-
sen et al. 2016). New technologies have the capacity to
simulate and predict the future epidemics and can
direct the public health authorities to respond in a
swifter way to infectious outbreaks of all kinds. A multi-
disciplinary approach has the potential to manage the
spread of pathogens and reduce the morbidity and
mortality. These novel tools can be harnessed for
mathematical modeling, risk mapping, phylogenetic
analysis, pathogen genome sequencing, and rapid on-
site diagnosis (Woolhouse et al. 2015). During 2001–
2003, a study in Gabon and RC recommended a
method for predicting and possibly prevent human
Ebola outbreaks by determining a correlation of wild
animal mortality with human Ebola outbreaks (Rou-
quet et al. 2005). To monitor the disease outbreak
effectively, it should be considered to gather data from
contaminated raw food products derived from bush-
meat and plants also (Mann et al. 2015).
In recent times, Internet-based surveillance tools
and epidemic simulation-based prediction can effi-
ciently facilitate the potential risk assessment and out-
break detection in infectious disease emergencies
which can prevent future infectious disease threats
(Christaki 2015). The widespread transmission that
occurred in the three most affected countries (Guinea,
Liberia, and Sierra Leone) in West Africa and the epide-
mic's designation as a ‘Public Health Emergency of
Table 4. Diagnostic kits developed for Ebola virus (EBOV) detection.
S.
No. Kit name Type of the test Input material(s) Company name, country
(1) – Antigen detection: LAMP Serum, plasma, amniotic, or synovial fluid Lucigen, USA
(2) ABICAP-rapid-Ebola test Antigen detection – antibody
immuno-column for analytical
purpose
Whole blood, serum, urine, stool, tears, and saliva
as well as in environmental samples such as





Nucleic acid detection: RT- PCR Serum or plasma Bioneer, Korea
(4) eZYSCREEN kit Antigen detection Blood or serum French Atomic Energy
Commission (CEA),
France
(5) LiferiverTM Ebola Virus
(EBOV) Real Time RT-PCR
Kit
Real-time reverse transcription PCR Blood, serum, plasma (non-heparin
anticoagulant)
Shanghai ZJ BioTech Co.,
Ltd., China
(6) LightMix Modular Ebola
virus Zaire
Real-time reverse transcription PCR Whole Blood Tib-molbiol/Roche,
Germany
(7) Lipsgene SEBOV/ZEBOV Kit Real-time reverse transcription PCR Blood, serum, or plasma Lipsdiag, Germany
(8) OraQuick® Ebola Rapid
Antigen Test Kit
Antigen detection Cadaveric oral fluid/whole blood OraSure Technologies, Inc.,
USA




Whole blood/serum/plasma BTNX Inc., Canada
(10) RealStar Filovirus Screen
RT-PCR Kit 1.0
Real-time reverse transcription PCR EDTA plasma Altona Diagnostics,
Germany






(12) SD Q Line Ebola Zaire Ag Antigen detection – lateral flow
chromatographic immunoassay
Blood or serum SD Biosensor Inc.,
GyeongGi-do, Republic
of Korea
(13) Xpert® Ebola Test Real-time reverse transcription PCR
in self-contained cartridge system
-
Whole blood EDTA or buccal swab specimens Cepheid AB, Sweden
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International Concern (PHEIC)’ insisted the formulation
of specific guidelines to efficiently manage the EBOV-
epidemic. In 2014 CDC, issued interim USA guidance
for ‘Monitoring and Movement of Persons with Poten-
tial Ebola Virus Exposure’ to guide CDC staff and public
health partners engaged in the response. The guidance
provided by public health authorities and collaborative
agencies with recommendations for monitoring travel-
ers who may be potentially exposed to Ebola and
therefore authorities can enforce the restriction in
movement. In humans, EBOV spreads through direct
contact with infected body fluids (blood, vomitus,
feces, semen, vaginal fluid, and urine) with broken skin
or exposed mucous membranes, and possibly through
sexual contact. Because of the risk for importing dis-
ease from infected travelers, in October 2014 the CDC
recommended that ‘all travelers to the United States of
America from Ebola-affected countries receive
enhanced entry screening and post-arrival active moni-
toring for Ebola signs or symptoms until 21 days after
their departure from an Ebola-affected country(CDC
2015). On 19 February 2016, the CDC-guidance expired
as Guinea was declared free of EBOV transmission
(after more than 45 days had passed since the last
EBOV case reported and the human-to-human trans-
mission ended).
New technology platforms are now being employed
vigorously for monitoring and surveillance of EBOV
(Cross et al. 2016). During 2014 EBOV outbreak, geno-
mic surveillance was performed using ‘next-genera-
tion’ sequencing (NGS) which helped in identifying the
EBOV origin and transmission (Gire et al. 2014). Further,
several start-ups are seriously designing the efficient
and portable devices for EBOV genomic surveillance. In
this line, a novel portable Nanopore DNA sequencing
instrument (Pennisi 2016; Quick et al. 2016) was devel-
oped and used in EBOV genome sequencing. The
Nanopore real-time genomic surveillance system was
transported in standard airline luggage to Guinea and
used for real-time genomic surveillance of the ongoing
epidemic during April 2015. Once received an Ebola-
positive sample, this portable system produced results
in less than 24 hours and genomic sequencing within
15–60 minutes. Such innovations warrant the use of
genomic surveillance in resource-limited settings in a
real-time manner. Rapid monitoring of potential out-
breaks, using such portable sequencer, is now a reality
in remote areas (Quick et al. 2016). Further, a handy,
portable, and compact (13.5 cm £ 8.5 cm £ 2.5 cm)
infection monitoring system was recently introduced
to monitor mass gathering places such as airports (Sun
et al. 2015). This highly mobile and hand-held system
can rapidly screen the non-contact vital signs using
two integrated sensors. One sensor which is a 24-GHz
microwave radar can measure the heart and respira-
tion rates and another sensor is a thermopile array for
capturing facial temperature. After collecting vital signs
data, the system detects infected individuals using a
linear discriminant function. Such devices can be very
useful in providing real-time updates and essential
resources for managing current Ebola outbreak with
the help of Global Ebola Response Monitoring and
Mapping System (WHO) and United Nations Mission
for Ebola Emergency Response (UNMEER) (Sun et al.
2015).
The global revolution of the Internet and social
media is a very powerful tool in disease surveillance.
Short message service (SMS)-based system has been
established to facilitate the active surveillance of indi-
viduals who are either returning from EVD-affected
countries or in contacts with EBOV-exposed local con-
firmed cases (Tracey et al. 2015). This SMS-system col-
lects the information on symptoms and temperature
twice daily and communicates to the public health
authorities (Tracey et al. 2015). During the August 2015
epidemic of EBOV in Sierra Leone, toll-free, nationwide
Ebola call centers were established by Sierra Leone's
Emergency Operations Center. This ‘alert’ system
proved to be very effective in providing health educa-
tion about EBOV to the callers and boosting public
reporting to public health officials about possible Ebola
cases and deaths (Miller et al. 2015). Based on a study
in southern Sierra Leone, the effectiveness of the cell
phone messaging technology has been proved to be
highly effective as a rapid communication tool for com-
munity epidemic surveillance from peripheral health
care facilities to higher levels (Jia & Mohamed 2015).
One recent report suggested that the utility of hybrid
information network in facilitating the quicker public
health measures may be possible, by integrating both
hierarchical and formalized command control-driven
and community-based, or ad hoc emerging networks,
which can efficiently employ social media to facilitate
the robust preparedness for the potential outbreak
and improving the capability of EBOV-identification
and diagnosis (Hossain et al. 2016).
A community-based effort in Liberia has been very
successful to defeat the EVD in recent times (Shrivas-
tava et al. 2016). These coordinated efforts involved
strong leadership and clear vision by the policy-maker
by declaring the disease as a public health priority to
all the concerned departments; actively involving the
community leaders by developing a sense of need
among them; increasing the level of faith and neutral-
izing any rumors about the disease among the local
people – by building see-through walls in treatment
centers so that people can watch the proceeding or
developing mechanism to respond promptly to trans-
port calls or by sensitizing the health professionals to
build confidence among local residents; strengthening
of the treatment facilities (by creating medical units,
treatment centers, logistics support) and laboratory
network by establishing five dedicated Ebola laborato-
ries; courageous attitude of the local volunteers;
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enormous support from the international community;
and well-coordinated national and international
response (Shrivastava et al. 2016). In response to the
2014 EVD-outbreak, a common international code,
ICD-10-CM code ‘A98.4’ (International Classification of
Diseases -10th Version-Clinical Modification) has been
implemented in all – in all health care institutions for
Ebola bio-surveillance specifically. This health care cod-
ing system will facilitate real-time tracking of EBD-out-
breaks (Chabra 2015). Since EBOV is a mutating RNA
virus, a rapid monitoring system using aptameric sens-
ing technology has been proposed for pandemic sur-
veillance (Acquah et al. 2015). Computer simulation
and mathematic modeling have been proposed to
quantify the West Africa Ebola epidemic (Chretien et al.
2015). International Society of Travel Medicine and
CDC collectively operate a global GeoSentinel surveil-
lance network of travel and tropical medicine clinicians
that collects de-identified demographic, diagnostic,
and travel information on ill travelers who cross inter-
national borders. GeoSentinel is composed of 63 clini-
cal sites in 29 countries on 6 continents. Through the
efforts of GeoSentinel surveillance network, differential
diagnosis of EVD in travelers arriving from Liberia,
Sierra Leone, or Guinea was conducted to track
the outbreak (Boggild et al. 2015). A similar approach
‘Surveillance and Outbreak Response Management
System (SORMAS)’ has also been suggested to support
the control of the EVD-outbreak (F€ahnrich et al. 2015).
In USA, to understand and address the doubts and
concerns of the citizens’ life twitter chat was con-
ducted thus such platforms can be very effective in
future to collect and disseminate the information in
future at the time of such outbreaks (Lazard et al.
2015).
Finally, the lessons learned from such epidemic with
high mortality emphasize that the efficient surveillance
system and coordinated global efforts involving every
social and political leader can be a best possible sce-
nario to prevent such deadly viral disease (Carney &
Weber 2015). Though CDC/WHO has officially declared
the end of the Ebola outbreak, the residual risks of
Ebola reintroduction or re-emergence are still haunting
the human population worldwide. According to the
Ebola Situation Report – 16 March 2016, the WHO has
strongly recommended the implementation of supe-
rior EBOV-monitoring systems in Guinea, Liberia, and
Sierra Leone to alert authorities for the EVD-clinical
cases or EVD-related death. Developed rich nations
must effectively implement a high-quality, robust
emergency response system, and provide the uncondi-
tional support to the establishment of sustainable
health care services in West Africa (Quaglio et al. 2016).
Only in this way we together can avert the next
humanitarian crisis due to EBOV or related viral
diseases.
10. Prevention and control
Currently, there is no robust and potent vaccine to con-
trol this lethal infection leaving prevention to be the
best way to escape from infection. Monitoring, surveil-
lance, isolating infected persons and treating them
separately, travel to the endemic area during outbreaks
should be discouraged, are the limited and effective
ways to prevent further spread of infection (Tambo
et al. 2014). For EVD-outbreak prevention, a new orga-
nization named as ‘United Nations Mission for Ebola
Emergency Response (UNMEER)’ has been created dur-
ing the 2014 outbreak of EBOV in Africa.
Various strategies like reporting of EVD-outbreak,
proper treatment to infected persons, proper burial of
dead persons, disinfection of the areas, and proper
planning to prevent further spread are the measures
taken to control EVD at national and international level.
Hospitals, where infected personals are treated, should
also be disinfected along with sterilization of all instru-
ments that come in contact with the infected persons.
Both incineration and autoclave can easily destroy the
virus. Fecal wastes should also be deactivated to
destroy the virus. Places, where there are no proper
facilities for incineration or autoclave should pack the
materials in a leak proof triple-layered container and
these should be transported to other places for sterili-
zation and disposal.
There is an urgent need for creating awareness
among the public about this deadly disease so that
spread of Ebola can be prevented (Salman et al. 2017).
Proper monitoring at airports and public places where
there are all possible chances for spread of infection is
of utmost importance (Brown et al. 2014; Read et al.
2015). People who fall ill should be kept under the
scanner for at least 21 days to rule out the infection.
Health care workers and doctors are also at higher risks
as they come in direct contact with the infected per-
sons. Hence, they should wear all protective wears like
gowns, gloves, face mask, goggles, and respirators and
also should follow barrier nursing. Collected samples
for diagnosis should be transported under high pre-
caution and handled only in the BSL4 lab. Climate
change has a huge role in the dissemination of various
diseases, and EBOV can also be transmitted to non-
human primates due to movement of bats as a result
of climate change (Dhama, Tiwari, et al. 2013). Since
bushmeat has been found to be the potential and
important source of many epidemics in the past, it is
important to monitor their illegal export to the na€ıve
countries (Mann et al. 2015).
11. Vaccines
Although EBOV was discovered in 1976 until now,
there is no effective vaccine or post-exposure
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treatment available. After the recent outbreaks, the
EVD management plan relies majorly on supportive
therapies. Since 2014 EBOV-outbreaks, the scientific
community is working tirelessly to develop immuniza-
tion regimen to control virus spread (Geisbert & Jahrl-
ing 2003). The prime-boost approach of DNA vaccine
followed by adenovirus vectored ZEBOV GP has
resulted in good cellular and humoral response in cyn-
omolgus macaques during experimental studies. DNA
vaccines are also in phase I of clinical trials. The glyco-
protein of EBOV has been a good target for eliciting
humoral immunity and surface protein targeted
human monoclonal antibody has provided a ray of
hope for a better vaccine (Nyamathi et al. 2003). These
DNA vaccines contain GP and NP of any of the five
strains of EBOV. It is administered intramuscularly and
followed by booster it generated an immune response
in 70% of volunteers with poor T cell response. DNA
vaccination may be further improved by vaccinating
through electroporation, injecting higher quantities, or
prime boosting with other antigen delivery platforms
(Sarwar et al. 2015). The problem in developing a pep-
tide-based vaccine to protect from this infection is due
to the vast similarity that exists between it and human
peptides. So, it is necessary to identify certain peptides
that are unique and conserved in EBOV to develop
peptide-based subunit vaccines (Kanduc, in press).
Experiments with lab animals like mice and guinea
pigs revealed that DNA vaccine protected them against
challenge with wild-type Mayinga 1976 strain of ZEBOV
(Gulland 2014).
Recombinant virus vectors are a good choice of
antigen delivery as they induce the cell-mediated
immune response, due to intracellular expression and
processing of antigen. Of note, Ad5 serotype is a popu-
lar adenovirus-based vector used for such purposes
due to ease in genetic manipulations and to grow to
high titers. In this approach, an E1 region of adenovirus
is replaced with GP of Ebola, and in non-human pri-
mates, it offered 100% protection in a single dose.
However, preexisting neutralizing antibodies limit the
utility of Ad vectors (Ledgerwood et al. 2010). Immuni-
zation in individuals having anti-Ad5 antibodies before
vaccination showed reduced cellular and humoral
response. Adenovirus-based vaccine (cAdVaxE) is a
bivalent vaccine against GP of ZEBOV and SEBOV
which has protected 100% of mice against challenge
(Wang et al. 2016). Another virus used include vesicular
stomatitis virus (VSV) which is an enveloped single-
stranded RNA virus. The recombinant VSV is produced
by replacing GP of VSV with GP of EBOV. When recom-
binant VSV-based filovirus vaccine is used in prime-
boost approach, it can give good protection. The VSV-
vectored vaccine expressing GP of filovirus has pro-
tected non-human primates against three species of
filovirus and Marburg virus (Mire et al. 2013). Further-
more, it has entered in phase III efficacy trial in Guinea.
It conferred protection in non-human primates using
different routes of immunization like mucosal, oral, or
intramuscular (Geisbert et al. 2009) with advantages
like transient viremia and self-limited febrile illness
(Sridhar 2015). Likewise, the recombinant human para-
influenza virus 3 (HPIV-3), a single-stranded, negative-
sense RNA virus, has been used as a vaccine candidate
owing to its ability to accommodate several GPs in the
viral backbone (Skiadopoulos et al. 2002). Intranasal
immunization with EBOV GP expressed with replica-
tion-competent HPIV3 showed better protection
against challenge with a higher parental dose of EBOV
(Yang et al. 2008). Other vectors like cytomegalovirus
(CMV)-based vaccine protected mice against EBOV,
and this has the potential to be used against EVD in
humans (Tsuda et al. 2015).
VLPs produced by expressing GP and VP40 in mam-
malian cells can also stimulate protective immune
response making better vaccine options (Cazares et al.
2016). GP-based fusion vaccines developed by EBOV
GP fused with Fc fragment of human IgG1 adjuvanted
with poly-ICLC have shown to induce a strong humoral
immune response and protect guinea pigs against
lethal EBOV challenge (Konduru et al. 2016). Subunit
vaccine contained GP protein expressed in Autographa
californica multicapsid nucleopolyhedrovirus, a baculo-
virus expression system in SF9 insect cells. Infected
cells are lysed and adjuvanted with Matrix-M, a phos-
pholipid constituent of synthetic cholesterol and sapo-
nin. This vaccine generated higher cellular and
humoral activity (Lovgren et al. 2011; Martins et al.
2016). With the use of reverse genetics, defective EBOV
without VP30 was found 100% effective in protecting
guinea pigs and mice (Hoenen et al. 2012). Replication-
defective vaccine by deleting VP30 has also been con-
sidered as an effective vaccination strategy to prevent
the infection (Saphire 2015).
Although WHO reported two vaccine candidates,
namely chimpanzee adenovirus-based, and VSV-based
EBOV vaccines, as are under phase III clinical trials,
there is a need to search for a safe and effective vac-
cine (Cohen 2014; Gulland 2014). Heterologous VSV-
and Ad5-vectored Ebola vaccine, GamEvac-Combi was
used in phases I and II trail which induced both
humoral and cellular immunity in all the 84 volunteers
(Dolzhikova et al. 2017). Presently, seven vaccines have
entered clinical trials (Chappell & Watterson 2017). Sci-
entists from the University of Texas, USA developed a
new EBOV inhalant vaccine that provides 67%–100%
protection in non-human primates. Most recently, a
recombinant VSV-Zaire ebolavirus vaccine (rVSV-
ZEBOV) is being tested under ‘Sierra Leone Trial to
Introduce a Vaccine against Ebola (STRIVE)’ program.
This promising candidate vaccine, which is in phase 2/
3 human trial, is the result of collaborative efforts
between the College of Medicine and Allied Health Sci-
ences, University of Sierra Leone, the Sierra Leone
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Ministry of Health and Sanitation, and the CDC. This
new vaccine is based on Zaire ebolavirus immunogen
and can only protect against Zaire ebolavirus, the
major agent behind EVD in West Africa (Folayan et al.
2016). Progress and advances in the area vaccines and
vaccination comprising of edible vaccine, peptide vac-
cine, DNA vaccine, immunomics-based vaccine, and
others need to be optimally utilized for designing and
developing effective vaccines along with exploiting
immunomodulatory approaches employing novel
adjuvants and vaccine delivery systems for improving
the efficacy of the EBOV vaccines (Dhama, Wani, et al.
2013; Delany et al. 2014; Sarwar et al. 2015; Singh et al.
2015).
12. Treatment
The recommended symptomatic treatments include
anti-inflammatory drugs for fever and pain, and intra-
venous fluids to maintain body osmotic balance. As
the kinome analysis revealed the involvement of mito-
gen-activated protein kinase (MAPK), phosphoinositide
3-kinases (PI3Ks), and calcium/calmodulin kinases in
EBOV infectivity, the PI3Ks inhibitor LY294002 and
CAMK2 inhibitor KN-93 were tested and found effec-
tive in reducing EBOV infection in Vero E6 cells. The
p38 MAP kinase has a role in activating the signaling
cascade leading to produce interleukins and TNFa. The
p38 MAPK inhibitor like SB202190 helps in ameliorat-
ing EBOV-mediated cytokine storm in human mono-
cyte-derived dendritic cells (Johnson et al. 2014).
Artemisinin, an antimalarial drug is also beneficial
regarding reducing the acute inflammatory response
(Ho et al. 2014). FTY720 is a drug used to treat patients
with autoimmune disorders and prevents transplant
rejection. Its sphingosine analog AAL-R helped in limit-
ing the inflammation in mice challenged with H1N1
influenza virus (Walsh et al. 2011).
As of now, to kill EBOV, we do not have a specific
anti-viral drug. Many anti-viral drugs are being tested.
Therefore, the current treatment relies only on sup-
portive therapy to revive. Recently, it has been discov-
ered that antibodies can effectively block the entry of
this virus so it can be employed as therapy for control
of Ebola infection in humans (Corti et al. 2016). There is
a search for a new drug to control lethality caused by
this virus (Choi & Croyle 2013; Kilgore et al. 2015). Clo-
miphene and Toremifene are estrogen receptor drugs
which were found to inhibit EVD infection in mice.
These drugs inhibit virus entry and also inhibit EBOV
fusion to host cells (Johansen et al. 2013). Ion channel
blocking agents like amiodarone were reported to
inhibit entry of EBOV into the cells (Gehring et al.
2014). These drugs combined with anti-viral drugs can
be candidates for the treatment of EVD in places where
medical facilities are less. Recently, a group of research-
ers has tested the anti-flu drug Favipiravir in EVD
treatment (Nagata et al. 2015; Sissoko et al. 2016)
which indicated its use in patients with medium to
high viremia. However, it turned out to be not effective
in the case of very high viremia (Sissoko et al. 2016).
Convalescent whole blood (CWB) and convalescent
plasma (CP) therapy intends to transfuse the blood/
plasma from disease survivors and helps in neutralizing
and reduce virus load, till the time patients own
immune system can destroy the invader (Van
Griensven et al. 2015). Up to 10 ml/kg BW of CP can be
obtained on 15 days interval from a plasma donor. It
has longer shelf-life. However, CP usage is superior to
CWB as there might be a problem of the immune
response against leukocyte antigens and febrile trans-
fusion reactions with the risk of bloodborne pathogen
transmission (Erhabor & Adias 2011). WHO also recom-
mended the use of whole blood products and conva-
lescent serum (Gulland 2014) during critical conditions.
Before transfusion, exhaustive testing of plasma is
required for residual EBOV RNA, and other potential
viruses like HIV, HBV, HCV, and syphilis. Purified IgG
from survivors given to challenged non-human pri-
mates two days post infection, prevented death, show-
ing the importance of antibody preparations (Dye et al.
2012). RNAi has been a promising technology that can
be used for the treatment of EBOV (Warren et al. 2010).
A pyrazine carboxamide derivative T-705 (Favipiravir) is
in the last phase of the clinical trial and has yielded sat-
isfactory results in a mouse model against EBOV. Favi-
piravir neither inhibits the DNA or RNA synthesis
(inhibit RNA-dependent RNA polymerase) in cell lines
of mammalian origin, nor it is toxic to cells (Oestereich
et al. 2014). Brincidofovir is a cidofovir analogue conju-
gated with lipid and also possesses anti-viral activity. It
has activity against dsDNA viruses but how it prevents
Ebola replication is still a question (Florescu & Keck
2014; Dunning et al. 2016). The broad spectrum anti-
viral agent alisporivir which inhibits the host protein
cyclophilin A (CypA) seems to have not much effect on
Ebola strains (Makona and Mayinga) as this virus does
not require CypA for replication (Chiramel et al. 2016).
BCX4430, viral RNA polymerase inhibitor was pro-
tective against EBOV in mice (Fauci 2014; Warren et al.
2014). A protein named double-stranded RNA binding
protein 76 (DRBP76) interacted with viral proteins, with
RNAs and with PKR, an interferon-induced anti-viral
kinase and also inhibited polymerase function of EBOV
(Shabman et al. 2011). The siRNA technology targeting
L-protein of RNA polymerase was used to inhibit EBOV
replication hence can be used as a post-exposure treat-
ment to EBOV infection (Geisbert et al. 2010). The siR-
NAs and phosphorodiamidate morpholino oligomers,
PMO aimed at ZEBOV RNA polymerase L-protein pre-
vented EVD in non-human primates (Warren et al.
2010; Geisbert et al. 2010). PMOs tend to target VP35
and VP24 that protects from the disease (Warren et al.
2015). Two new drugs based on antisense PMOs (AVI-
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Table 5. Different available therapies for Ebola virus treatment.
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GP/NP Mice and guinea
pigs
NA Pushko et al.
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Bispecific antibody Specific for NCP1 or GP
receptor binding site
coupled to mAb against
conserved surface
exposed GP epitope
Mice NA Wec et al. (2016)
Human
transbodies
Cell penetrable human ScFv against
VP40
Inhibit egress of EBOV VLPs
from hepatocytes
In vitro NA Teimoori et al.
(2016)
TmPyP4 Cationic porphyrin Inhibition of L gene of
EBOV
In vitro NA Wang et al.
(2016)
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6002, AVI-6003) and lipid nanoparticles (LNP)/siRNA
(TKM-Ebola) are in phase I clinical trials. Encapsulation
with LNP gives an effective drug delivery, but they
need several dose regimens to achieve efficacy (Choi &
Croyle 2013; Thi et al. 2015). The miRNA technology
has also shown good results during in vitro trials
(Sheng et al. 2014). Understanding the mechanism of
virus entry through two-pore channels paved the way
in testing certain molecules such as Tetrandrin that
inhibits or halts virus entry into the cells and prevents
the disease (Sakurai et al. 2015).
Meanwhile searching for new drugs, some of the
drugs have been repurposed for therapy (Table 5).
Chloroquine and its structural analogs including
hydroxychloroquine, pamaquine, primaquine, and
plasmaquine, etc. are antimalarial drugs. These are also
considered as a lysosomotropic agent that prevents
endosomal/lysosomal acidification. Based on the litera-
ture data, such endosomal/lysosomal acidification inhi-
bition by potential therapeutic agents such as
chloroquine are highly effective against viral infections
and associated pathologies such as of EBOV. Intraperi-
toneal administration of chloroquine protected 100%
of monkeys challenged with EBOV with a dose of 90
mg/kg BW, 4 hours before infection (Olsen et al. 2013).
Of note, in Liberia when the mass administration of the
antimalarial drug was adopted, reduction in fever sta-
tus was observed during Ebola outbreak (Kuehne et al.
2016). Rosuvastatin, atorvastatin, and pravastatin are
the statins which reduce inflammatory action and are
known to reduce C-reactive protein (CRP) and TNFa. It
also hampers cholesterol supported EBOV membrane
biosynthesis (Haque et al. 2015). EBOV infection leads
to overexpression of the procoagulant tissue factor
and endothelial cells also participate in coagulation
disharmony characteristic of Ebola infection. In
macaque model recombinant nematode anticoagulant
protein c2 (rNAPc2) improved survival and provided an
additional therapeutic regimen which can be adapted
along with several other therapies (Geisbert et al.
2003b). Suramin which is used as an anti-trypanosomal
agent can also be used as an anti-viral agent to treat
EVD and Chikungunya due to its competitive anti-hep-
arin activity. It also can interfere with viral replication
and viral entry into the cell (Henß et al. 2016). In the
face of unavailability of any suitable treatment proce-
dures for curing the affected persons of this dreaded
disease, use of passive immunization (neutralizing anti-
bodies) protocol was opted by transferring the sera
from healthy persons which recovered from EVD
(Saphire 2013). But it is not sufficient alone to give
100% protection after the onset of viremia (Mire et al.
2016). Additionally, ZMapp which possess humanized
mouse antibodies showed promising results in non-
human primates (Wong, Qiu, et al. 2014; Zhang et al.
2014) and consequently, on 12 August 2014, the WHO
approved the use of ZMapp for the treatment of EVD.
These mAbs are expressed in the glycomodified Nic-
othiana benthamiana and found to be carrying better
anti-EBOV efficiency in animal models (Zhang et al.
2014). Bispecific Trojan-horse antibodies that can
broadly neutralize all known filoviruses were found to
protect mice from multiple EBOV infection (Wec et al.
2016). Recently, attempts have been made to evaluate
the anti-Ebola potential of human scFvs against VP40
envelope protein of EBOV that plays an important role
in its life cycle. These antibodies were found to block
the Ebola VLPs in hepatic cells which are transduced
with pseudo-Lentivirus particles (Teimoori et al.2016).
This suggests that these transbodies might be effective
against EBOV as well interfering with their replication
in the cell. Also, it has been found that there exists a
conserved guanine-rich sequence within the L gene of
EBOV that can form quadruplex RNA and it can be tar-
geted by cationic porphyrin TmPyP4 that leads to inhi-
bition of L gene expression (Wang et al. 2016).
Progress is on the way towards developing effective
therapeutics as some lead has been obtained by identi-
fying the weak spots in EBOV structure. Looking into
the demand of ZMapp and existing limited
manufacturing facilities, an alternative approach such
as the use of the plant as bioreactors for the bulk pro-
duction of ZMapps, have been proposed. Certain host
factors are also responsible for virus replication and
survival. To identify them insertional mutagenesis can
be employed which is a high-throughput method
where host genes are disrupted. This helps in identify-
ing those genes required for virus replication and can
be used as a drug target in future (Cheng et al. 2016).
This gives direction to further identification of viral tar-
gets or host targets which could be used to control or
inhibit this virus disease in the patient. Molecular dock-
ing studies of EBOV-glycoproteins have been carried
out recently which could provide insights into drug
designing (Ahmad et al. 2016; M Alam El-Din et al.
2016). Advances in designing effective therapeutic
agents and drugs by utilizing emerging and upcoming
options, namely cytokines, recombinant proteins, RNAi
technology, Toll like Receptors, avian egg antibodies,
nano-medicine, immunomodulators, probiotics herbs,
need to be explored to the desired potential to counter
EBOV (Geisbert et al. 2010; Dhama, Chakraborty, et al.
2013; Dhama, Saminathan, 2015; Malik et al. 2013; Gao
& Yin 2014; Arntzen, 2015; Streatfield et al. 2015; Yao
et al. 2015; Cross et al. 2016; Iqbal et al. 2016).
13. Conclusions and future perspectives
EVD is one of the most common examples to refer
emerging or re-emerging zoonoses globally. Nonethe-
less, the disease is known since 1976, its severity,
exceptional infectious or contagious nature, acquiring
pandemic status during 2014–2015, has raised numer-
ous questions before the health professionals and
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policy-makers. The emergence of Ebola as a threat has
cautioned all of us to get ready with arsenals for con-
tending Ebola-like diseases through multidisciplinary
and collaborative approaches overcoming the national
boundaries. This is the right time to tackle the EVD
emergency through the development and use of state-
of-art tools and techniques befitting for confirmatory
diagnosis, developing internationally suited surveil-
lance, monitoring, and networking systems as well as
identifying the animal reservoirs. The urgency for
developing and use of both, the safe and efficacious
vaccine and affordable anti-viral drugs are desperately
needed. Kinome, transcriptome, and exome analyses
may be helpful in identifying the genomic targets up
or down-regulated and also insight into siRNA and
miRNA generated during infection helping in develop-
ing efficacious therapeutic regimens. This is an apt
time to think of for ‘One Health’ concept and come out
with a strategy to safeguard human, animal, and envi-
ronment. Realizing the eventual impact of the threat
imposed by EVD, all pinpointed efforts must be
focused on achieving the goal of preventing and con-
trolling the existence of EVD timely. The Ebola epi-
demic has been a humanitarian crisis in the three
worst affected countries in West Africa. Although WHO
has declared the end of Ebola, there is still a potential
risk of sporadic transmission of EBOV which could be
largely due to residual virus persistence in some survi-
vors in West Africa (Brainard et al. 2016). The WHO is
urging public health authorities to remain on high alert
and ready to respond in any emergency (Stamm 2015).
Further, strong surveillance and emergency response
capacity need to be upheld, while care, screening, and
counseling also need to be provided for survivors.
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